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Abnormal phosphorylation and aggregation of the microtubule-associated protein Tau are 
neuropathological hallmarks of various neurodegenerative disease called tauopathies, such as 
Alzheimer’s disease and frontotemporal dementia. Numerous complex cellular mechanisms 
are involved in regulation of Tau phosphorylation but remain incompletely understood at the 
molecular level. The development of a novel live-cell reporter system based on protein-
fragment complementation assay (PCA) enables studying dynamic changes in the status of 
Tau phosphorylation. In this assay, complementary fragments of Gaussia princeps luciferase 
protein are fused with Tau and Pin1 (peptidyl-prolyl cis-trans isomerase) proteins, and serve 
as a reversible real-time sensor of protein-protein interaction. Pin1 has an essential role regu-
lating the dephosphorylation of Tau at multiple disease-associated, proline-directed phophory-
lation sites in neurons. The PCA assay system suits well for studying dynamic protein-protein 
interactions of Tau in live cells. In a chemical library screen performed using this assay, seve-
ral !-aminobutyric acid type A (GABAA) receptor modulators were identified as novel regula-
tors of Tau phosphorylation regulators. These structurally distinct GABAA receptor modula-
tors increased the Tau-Pin1 interaction and promoted specific phosphorylation of Tau at the 
AT8 epitope (Ser199/Ser202/Thr205) in mature cultures of cortical neurons. The increase of 
this specific Tau phosphorylation induced by GABAA active molecules was associated with 
reduced binding to protein phosphatase 2A, a major phosphatase contributing to Tau 
dephosphorylation, without any reduction of enzymatic activity of protein phosphatase 2A per 
se in a cell-free assay. These data provide new insight in the different mechanisms of Tau 
regulation and functions, which is essential for more detailed understanding of basic neuro-
biology and mechanisms of neurodegeneration. 
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Mikrotubulus-assosioituneen Tau proteiinin epänormaali fosforylaatio ja aggregoituminen 
ovat ominaisia neuropatologisia tunnusmerkkejä useille hermorappeumasairauksille, tauopa-
tioille, kuten Alzheimerin tauti ja frontotemporaalinen dementia. Useat monimutkaiset mole-
kulaariset mekanismit ja post-translationaaliset modifikaatiot jotka vaikuttavat Tau:n fosfory-
laatioon ovat tällä hetkellä vaillinaisesti ymmärrettyjä. Uuden solupohjaisen reportterisystee-
min kehitys, joka pohjautuu proteiinifragmenttien komplementaatiomenetelmään, mahdollis-
taa Tau:n fosforylaation dynaamisten muutosten tutkimisen elävissä soluissa. Kehitetyssä 
menetelmässä Gaussia princeps-lusiferaasiproteiinin komplementaariset osat on yhdistetty 
Tau ja Pin1 (peptidyyli-prolyyli cis/trans isomeraasi) proteiineihin, ja reportteriproteiinin ak-
tiivisuus toimii sensorina proteiini-proteiinivuorovaikutuksen muutoksissa. Hermosoluissa 
Pin1 on keskeinen Tau:n defosforylaation säätelijä useissa tautispesifisissä proliini-ohjatuissa 
fosforylaatio tähteissä. Kehitetty menetelmä soveltuu hyvin Tau:n proteiini-
proteiinivuorovaikutusten tutkimiseen. Tätä menetelmää käyttäen suoritetulla kemiallisten 
aineiden seulonnalla löydettiin useita !-aminovoihappo tyyppi A:n (GABAA) reseptorimodu-
laattoreita, jotka säätelevät Tau:n fosforylaatiota. Seulonnassa idenfifioidut rakenteellisesti 
toisistaan poikkeavat GABAA–reseptorimodulaattorit lisäsivät Tau-Pin1 vuorovaikutusta, 
sekä lisäksi indusoivat Tau:n fosforylaatiota erityisesti AT8 fosfoepitoopissa 
(Ser199/Ser202/Thr205) kypsissä kortikaalisten hermosolujen viljelmissä. Näiden GABAA–
aktiivisten molekyylien indusoima Tau:n fosforylaatio liittyi vähentyneeseen sitoutumiseen 
proteiinifosfataasi 2A:n (PP2A) kanssa, joka on Tau:n defosforylaation kannalta keskeinen 
fosfataasi. PP2A:n entsyymiaktiivisuuden vähenemistä ei kuitenkaan havaittu soluvapaassa 
aktiivisuusmäärityksessä. Erilaisten Tau:n fosforylaatioon ja biologisiin tehtäviin vaikuttavien 
mekanismien tutkiminen on välttämätöntä yksityiskohtasemman ymmärryksen saavuttami-
seksi niin perus neurobiologiassa, kuin myös hermorappeumaan johtavissa mekanismeissa. 
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1 INTRODUCTION 
In the complex cellular environment, an immense amount of molecular interactions defines 
the fate of a cell. Particularly, dynamic network of protein-protein interactions (PPIs) govern 
to the functionality of the cell mostly via the formation of multi-protein complexes. Regard-
less of intense research in this area, the interaction patterns of proteins within the cell are 
poorly understood. However, aberrations in PPIs are widely recognized to associate with nu-
merous pathological disorders which affords an opportunity for developing novel therapeutic 
strategies by modulating the pathophysioligically relevant PPIs (Arkin & Wells 2004). 
 Cerebral aggregation of misfolded proteins is a common pathological feature of several 
neurodegenerative disorders (e.g. Lee et al. 2001; Ballatore et al. 2007). A group of neurode-
generative disorders that are charactherized by intracellular inclusions of abnormally phos-
phorylated microtubule-associated protein tau (MAPT) are collectively known as tauopathies. 
These prominent and progressive intracellular tau inclusions, called neurofibrillary tangles 
(NFTs), are accumulations of filamentous tau deposits. Lesions in the central nervous system 
(CNS), including neuronal degeneration and consequent brain dysfunction, are neuropa-
thological hallmark features of these dementias and movement disorders, such as Alzheimer’s 
disease (AD) and frontotemporal dementias, that are linked to aberrant tau phosphorylation. 
Despite of the incomplete knowledge of these specific lesions mentioned, the exact temporal 
stages of neuropathology and even the divergence of disease phenotypes of various 
tauopathies, the synergistic contribution of aberrant tau functions to tau-mediated neurode-
generation has become more evident. Importantly, the combination of both functional abnor-
malities, toxic gain-of-functions and loss of normal tau function(s) is capable and sufficient to 
cause neurodegenerative disorders independently of other disease-specific aberrations (e.g. 
Spillantini et al. 1998; Hutton et al. 1998).  
 Establishing the specific roles of various protein aggregates to the onset and progression of 
the disease is essential for discovering the mechanism(s) of disease pathology (Ballatore et al. 
2007). Howerer, investigation of these early molecular events contributing to the disease on-
set is highly challenging. There are many aspects that hinder the studies of these dynamic 
processes that may take even years to manifest. In the case of tau, there are some contradic-
tions of cause-and-effect functions of diverse neurotoxic tau species and their contribution to 
disease pathology and the possible pre-aggregated or pre-fibrillary forms further complicates 
the study designs and may cause misinterpretation of data. Also, in addition to the well-
established function of tau in promoting the assembly and stabilizing the stucture of microtu-
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bules, tau may also possess other functions that are not that well characterized, for example 
interactions with other proteins and enzymes (Buee et al. 2000). Furthermore, besides abnor-
mal phosphorylation tau undergoes numerous other post-translational modifications of which 
some could have more or less pronounced effects on the formation of NFTs (Gong et al. 
2005). Thus, combined effects of these modifications comprise a complicated system to alter 
the tau protein, and this system likely contributes to attenuation or exacerbation of the disease 
onset and progression of tau-mediated neurodegeneration. 
 Identification of multiple events in the cascade finally leading to tau-driven neurodegen-
eration is instrumental in order to search for novel therapeutic approaches and drug candidates 
for tauopathies (e.g. Ballatore et al. 2007). As PPIs are vital for cellular function, investigat-
ing the protein-protein interactions of tau may eventually improve our understanding of this 
highly complex pathway and shed new light towards the key factors to arrest, or at least to 
slow down the progession of these devastating neurodegenerative disorders. Because of many 
of these disases have a great tendency of being hardly detected in their early pathogenesis, it 
is high of an importance to try to address the investigation methods towards these early 
events.   
2 BIOLOGY OF TAU PROTEIN 
2.1 Structure and functions 
Microtubules (MTs) are components of the cytoskeleton, a cellular structure that is vital in 
axon and dendrite formation, which both contribute to the intracellular transport of numerous 
molecules and to neurotransmission (e.g. Meraz-Rios et al. 2010). Microtubule-associated 
protein tau (MAPT) is a major cytoskeletal-associated protein, which is encoded by a single 
gene that is located on human chromosome 17q21 containing 16 exons (figure 1) (Neve et al. 
1986). The primary transcript of tau contains 13 exons, since exons 4A, 6 and 8 are specific 
for peripheral tau and are not present in the human brain mRNA (Buee et al. 2000). Exons 1, 
4, 5, 7, 9, 11, 12 and 13 are constitutive exons of tau protein, unlike exons -1 and 14, which 
are both transcribed but not translated into a protein (Goedert et al. 1989a).  
There are six tau isoforms found in the human brain, produced by alternative splicing of 
exons 2, 3 and 10 in tau mRNA (figure 1) (Goedert et al. 1989a; Andreadis et al. 1992), from 
which exon 3 is exon 2 dependent, i.e. exon 2 can appear independently but exon 3 never ap-
pears if exon 2 is absent (Andreadis et al. 1995). These six tau isoforms (with exon combina-
tions of 2-3-10-; 2+3-10-; 2+3+10-; 2-3-10+; 2+3-10+; 2+3+10+) vary in lenght ranging from 
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352 to 441 amino acids (Goedert et al. 1989a; Goedert et al. 1989b; Kosik et al. 1989). Tau 
protein can be structurally divided into two domains: the projection domain and the microtu-
bule-binding domain (MBD) (e.g. Wang & Liu 2008; Meraz-Rios et al. 2010). The projection 
domain, which is located at the amino-terminal end of tau molecule, is suggested to project 
from the microtubule surface (Hirokawa et al. 1988), and can be further divided into two re-
gions (e.g. Wang & Liu 2008; Meraz-Rios et al. 2010). The C-terminal region of the projec-
tion domain is enriched with proline residues and is positively charged, whereas the N-
terminal part has a positive charge and contains mainly acidic residues. In the N-terminal re-
gion there are two or one or zero 29 amino acid sequences (2N, 1N, 0N, respectively) encoded 
by exons 2 and 3. This domain is followed by proline-rich region that modifies the lenght of 
the N-terminus of the projection domain, thereby naturally modifying the lenght of the entire 
tau protein (e.g. Buee et al. 2000). Although the exact function of the projection domain is yet 
to be determined, it has been reported to interact with cytoskeletal proteins other than tau, e.g. 
neurofilaments and plasma membrane (Hirokawa et al. 1988; Brandt et al. 1995). Also, a 
regulatory role has been described for proline-rich region in the interaction between tau and 
microtubules via phosphorylation (e.g. Lee et al. 2004). 
Among the neuronal microtubule-associated protein (MAP) family including MAP1, 
MAP2 and tau (e.g. Iqbal et al. 2005), tau is functionally the major microtule-associated pro-
tein in neurons (Weingarten et al. 1975). The main function of tau is to stabilize and promote 
the assembly and disassembly of microtubules. The binding of tau to microtubules occurs via 
microtubule-binding repeats encoded by exons 9-12 that are localized in the MBD at the C-
terminal part of tau protein (Lee et al. 1989). Also, MBD can be further divided into microtu-
bule-binding domain per se and to an acidic region that forms the C-terminal region of MBD 
(e.g. Wang & Liu 2008; Meraz-Rios et al. 2010). The actual MBD contains either three (3R-
tau, repeats R1, R3, R4) or four (4R-tau, repeats R1, R2, R3, R4) repetitive sequences of 31 or 
32 amino acid residues, which are similar but not identical (Lee et al. 1989; Iqbal et al. 2009). 
These different isoforms, i.e. whether the R2-repeat is absent (3R-tau) or present (4R-tau), are 
result of alternative splicing of exon 10 that encodes the R2-repeat (e.g. Andreadis et al. 1992; 
Hernandez & Avila 2007). 
All the six isoforms of tau (2N/4R, 1N/4R, 0N/4R, 2N/3R, 1N/3R, 0N/3R) have been 
found in the adult human brain, but only the shortest isoform, 0N/3R, is expressed in fetal 
human brain (Kosik et al. 1989; Goedert et al. 1989b). The inclusion of additional R2-repeat 
in the 4R-tau and the presence of one or both N-terminal inserts (1N and 2N) enhances the 
microtubule-binding affinity, thereby making the longest isoform (2N/4R) the most efficient 
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in promoting MT-assembly (e.g. Lu & Kosik 2001; Alonso et al. 2001b). Additionally to R2-
repeat, a specific peptide sequence within the inter-region between repeats R1-R2 is sug-
gested to be the most potential region for inducing microtubule polymerization (Goode & 
Feinstein 1994). 
 
 
 
Figure 1. Tau encoding MAPT gene, primary transcript and domain structures of six human 
tau isoforms expressed in the central nervous system. The human MAPT gene that encodes 
tau protein is located at the chromosome 17 position 17q21. From the 16 exons of the MAPT 
gene, 13 exons are transcribed in the primary transcript, since exons 4A, 6 and 8 are specific 
for peripheral tau and are not present in the human brain mRNA. Exon -1, which is part of the 
promoter, and exon 14 are both transcribed but not translated into a protein. There are six tau 
isoforms found in the human brain produced by constitutive exons 1, 4, 5, 7, 9, 11, 12 and 13, 
and alternative splicing of exons 2, 3 and 10. Differences between the six human tau isoforms 
are due to presence or absence of one or two amino-terminal inserts of 29 amino acids (0N, 
1N, 2N) encoded by exons 2 and 3 combined with carboxy-terminal inserts of either 3 (R1, 
R3 and R4) or 4 (R1-R4) repeat-regions. R2 repeat-region is encoded by exon 10. These six 
tau isoforms vary in lenght including 352, 381, 383, 410, 412 or 441 amino acids (with exon 
combinations of 2-3-10-; 2+3-10-; 2-3-10+; 2+3+10-; 2+3-10+; 2+3+10+, respectively). All 
tau isoforms have been found in the adult human brain, but only the shortest isoform 2-3-10- 
(0N/3R), is expressed in fetal human brain (modified from Bueé et al. 2000).  
 
Besides the regulatory role of tau in microtubule dynamics, other possible physiological 
functions have been reported. Tau has been found to be localized in the cell nucleus in the 
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human brain, and in contrast to cytosolic tau, nuclear tau is found to be less soluble, implicat-
ing the role of specific modifications which may either post-translational or mediated via in-
teraction with other proteins (Brady et al. 1995). Moreover, tau is reported to bind RNA 
through MBDs leading to a subsequent induction of paired helical filament (PHF) formation 
(Kampers et al. 1996). Tau is also found to contribute to cell viability by antagonizing apop-
tosis (Li et al. 2007) and to interfere with binding of kinesin and kinesin-like motor proteins 
to microtubules and thereby disrupting the axonal transport (Tatebayashi et al. 2004). Until to 
date and according to its physiological functions, tau has been mainly considered as an axonal 
protein. However, a recent study has reported a novel dendritic role of tau (Ittner et al. 2010). 
These results suggest that tau mediates A!-toxicity in AD. The postsynaptic targeting of Fyn, 
a Src-family tyrosine kinase, that involves the interaction of Fyn with the projection domain 
of tau, was found to be reduced in knockout mice resulting in decreased phosphorylation of its 
substrate NMDA receptor. This reduced phosphorylation of NMDA receptors decreases 
NMDA receptor-mediated excitotoxicity thereby mitigating the A!-toxicity.  
2.2 Regulation of phosphorylation and dephosphorylation 
The biological activity of tau, like other phosphoproteins, is regulated by the degree of its 
phosphorylation (e.g. Kopke et al. 1993; Alonso et al. 1994). Like tau expression, also phos-
phorylation of tau is developmentally regulated (Goedert et al. 1993). The shortest isoform 
(0N/3R) of tau is highly phoshoporylated in the fetal and postnatal human brain, whereas its 
phosphorylation is markedly decreased within the healthy adult brain. Interestingly, tau is also 
functionally regulated, for example as seen in increased phosphorylation states during the 
mitotic stage of cell cycle (Delobel et al. 2002). Hence, both developmental and functional 
regulation of tau phosphorylation may play a crucial role in the regulation of microtubule sta-
bilization and dynamics during the normal neurite formation and other MT-dependent func-
tions (e.g. Wang & Liu 2008). Furthermore, tau proteins that are hypophosphorylated or hy-
perphosphorylated loses their ability to bind to microtubules, thus indicating that phosphory-
lation at certain sites at tau is required for optimal binding to microtubules and maintain the 
function to stabizile their structure (Garcia de Ancos et al. 1993). In contrast, phosphorylation 
at specific sites may prevent this stabilizing role of tau and may promote its self-aggregation.  
Tau phosphorylation is catalyzed by several protein kinases which each has specific pref-
erence towards specific phosphorylation regions or sites of tau (table 1) (e.g. Liu et al. 2007). 
There are more than ten kinases capable to phosphorylate the serine (Ser) and threonine (Thr) 
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residues of tau in vitro. The kinases that phosphorylate tau can be further divided into two 
distinct groups: proline-directed protein kinases and non-proline-directed protein kinases 
(PDPKs and NPDPKs, respectively), according to their motif-specifity (e.g. Wang & Liu 
2008; Meraz-Rios et al. 2010). The PDPKs includes kinases such as GSK-3!, CDK5, 
DYRK1A, MAPK and ERK1/2, of which the GSK-3! is the most strongly associated to con-
tribute to the abnormal hyperphosphorylation of tau in AD pathogenesis (e.g. Grimes & Jope 
2001; Gong et al. 2005; Wang & Liu 2008). The NPDPKs involved in tau phoshorylation 
include e.g. PKA, PKC and CaMKII. Opposite to phosphorylation, all the major protein 
phosphatases (PPs) excluding PP2C, can dephosphorylate tau (Liu et al. 2005). Among the 
PPs (PP1, PP2A, PP2B, PP5), PP2A contributes with the highest efficacy on tau dephos-
phorylation. In addition to kinases and phosphatases mediating the tau phosphorylation, its 
conformational state regulates the rate and extent of its phosphorylation (e.g. Alonso Adel et 
al. 2004). The conformational changes may promote tau as a more suitable substrate for 
kinases and or may decrease the efficacy of dephosphorylation by making tau worse substrate 
to protein phosphatases (e.g. Iqbal et al. 2005). Priming phosphorylation of tau by certain 
NPDPKs markedly stimulates the subsequent phosphorylation by PDPKs thereby promoting 
hyperphosphorylation (e.g. Liu, S.J. et al. 2004). 
The longest human brain tau isoform (2N/4R) consisting of 441 amino acids cointains 80 
putative Ser and Thr residues altogether, from which more than 30 has been identified to be 
phosphorylated in PHF-tau of AD brain (e.g. Gong et al. 2005; Wang & Liu 2008). The ma-
jority of these sites are localized in the proline-rich region (residues 172-251, numbering ac-
cording to the longest isoform 2N/4R) and C-terminal region (residues 368-441) flanking the 
MBD, with the exception of sites Ser262 (R1), Ser285 (R1-R2 inter-repeat), Ser305 (R3-R4 
inter-repeat), Ser324 (R3), Ser352 (R4) and Ser356 (R4) which are localized in the MBD (e.g. 
Gong et al. 2005; Liu et al. 2007; Wang & Liu 2008). The hyperphosphorylation of MBD-
localized sites has been proposed to have more detrimental effect on microtubule assembly 
promotion and stabilization compared to the other sites of tau.  
The hyperphosphorylation of tau could be the result of impaired balance between the 
phosphorylation and dephosphorylation caused by upregulation of kinase activities and/or 
downregulation of phosphatase enzyme activities (e.g. Gong et al. 2005). However, among 
the over 30 sites of PHF-tau that has been found to be phosphorylated, the crucial sites in-
volved in the development of AD pathology has been poorly understood. Also, there has been 
a debate for years whether the abnormal hyperphosphorylation per se is sufficient to induce 
neurotoxicity and neurofibrillary pathology seen in AD and related tauopathies. Interestingly, 
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the results of recent study suggests that combined phosphorylation of tau at sites Thr212, 
Thr231 and Ser262 can induce tau aggregation, cause disruption of MT-network and neuro-
toxicity and concomitant neurodegeneration and apoptosis (Alonso et al. 2010). These results 
provides in vitro evidence of the contribution of abnormal tau hyperphosphorylation to neu-
rofibrillary degeneration and identifies some phosphorylation sites that induce the conversion 
of tau to toxic molecule thereby losing its ability to maintain normal function. Furthermore, 
additional sites that are suggested to facilitate the conversion of tau into toxic protein includes 
Ser199, Ser202, Thr205, Ser235, Ser356, Ser396, Ser404 and Ser422 (Alonso Adel et al. 
2004). 
2.2.1 Kinases  
2.2.1.1 GSK-3! 
Glycogen synthase kinase-3 (GSK-3) is a proline-directed (serine or threonine preceding 
proline) serine/threonine protein kinase, which in mammals, is encoded by two genes, gsk-3! 
and gsk-3" (Woodgett 1990). The two isoforms of the end products of these two genes, GSK-
3# (~51 kDa) and GSK-3! (~47 kDa), are abundant in the brain. These two GSK-3 isoforms 
are highly homologous, but have differencies in their N- and C- terminal regions (e.g. Avila et 
al. 2010). As a crucial regulatory enzyme, GSK-3 has multiple functions including phosh-
porylation of several substrates and regulating various physiological processes such as signal 
transduction and glycogen metabolism (e.g. Grimes & Jope 2001).   
 GSK-3 activity is modified by its phosphorylation of an N-terminal serine (Ser21 in GSK-
3# and Ser9 in GSK-3!) (Jope & Johnson 2004). Protein kinase A (PKA) and Akt are few of 
the group of priming kinases which can phosphorylate these serines and, thereby, reduce the 
activity of GSK-3. In contrast to reducing the activity of GSK-3, tyrosine phosphorylation 
(Tyr279 in GSK-3# and Tyr216 in GSK-3!) increases the enzyme activity. Furthermore, 
many of the GSK-3 substrates must be primed (pre-phosphorylated) for subsequent phos-
phorylation by GSK-3, hence the phosphorylation state of the substrates also regulate GSK-3 
activity towards them. Other way to regulate GSK-3 activity includes its interaction with 
other proteins and protein complexes (Avila et al. 2010) and also its subcellular localization, 
since GSK-3 has been found in various cellular compartments (Grimes & Jope 2001). 
  Besides that GSK-3 interacts with APP, another hallmark protein in AD, it has been re-
ported that, especially GSK-3! isoform, can phosphorylate tau on several sites (e.g. Grimes & 
Jope 2001). As a one of the main kinases phosphorylating tau, GSK-3 participates to regula-
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tion of phosphorylation equilibrium of tau under normal physiological conditions. In contrast, 
it highly contributes to abnormal phosphorylation of tau and subsequent dissociation of tau 
from the microtubulus. However, the phosphorylation of primed sites of tau by GSK-3! 
seems to have more significant effect on its interaction with microtubulus compared to phos-
phorylation at non-primed sites (Cho & Johnson 2003). There have also been implications 
that Ser9-phosphorylated GSK-3!, which is associated with reduced kinase activity, can 
phosphorylate tau through unknown mechanism (Yuan et al. 2004).  
2.2.1.2 CDK5 
Cyclin-dependent kinase 5 (CDK5) has a crucial role in the development and maintenance of 
the central nervous system by phosphorylation of a large number of substrates (Cruz & Tsai 
2004a). In addition to GSK-3, CDK5 is another main proline-directed serine/threonine kinase 
regulating the phosphorylation state of tau. For enzyme activity, CDK5 has to associate with 
its regulatory subunits, p39 and p35, for its normal functions. The activators p35 and p39 are 
mainly expressed in post-mitotic neurons thereby restricting the CDK5 activity mostly to the 
central nervous system (Lew et al. 1994).  
The neurotoxicity of CDK5 deregulation contributes to pathogenesis of various neurode-
generative disorders, such as AD (Cruz & Tsai 2004b). Under neurotoxic conditions (e.g. 
ischemic or oxidative damage) calpain cleaved truncated forms of the activators p39 and p35, 
p29 and p25, respectively, are generated (Kusakawa et al. 2000; Patzke & Tsai 2002). These 
cleaved forms are more stable thereby prolonging the activity of p25/p29-CDK5 heterodimer. 
Also, by binding to p25, subcellular localization of p25-CDK5 complex is changed compared 
to p35-CDK5 complex (Cruz & Tsai 2004b) and the substrate specifity is altered (e.g. Patrick 
et al. 1999). The generation and accumulation of p25 e.g. in AD brains causes tau hyperphos-
phorylation and induces cytosceletal disruption and apoptosis in neuronal cells (Patrick et al. 
1999).  
2.2.1.3 DYRK1A 
The dual-specifity tyrosine (Y)-phosphorylation-regulated kinase 1A (DYRK1A) is a proline-
directed serine/threonine protein kinase that has recently been related to tau phosphorylation 
(e.g. Ryoo et al. 2007). DYRK1A is a multifaceted enzyme that phosphorylates several pro-
teins and has dual substrate specifity: it autophosphorylates on the threonine231 residue in the 
activation loop of the catalytic domain for its self-activation (Himpel et al. 2001) and the tar-
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geted phosphorylation of serine/threonine residues of various proteins (Himpel et al. 2000). It 
has been also suggested, that DYRK1A primes various substrates, e.g. tau, to be subsequently 
phosphorylated by GSK-3 (Woods et al. 2001). 
The gene encoding the kinase is located in the human chromosome 21, the same chromo-
some which full or partial trisomy causes Down syndrome (DS) (e.g. Wiseman et al. 2009). 
Many of the genes that are encoded in this chromosome are, due to an additional copy, over-
expressed leading to various deficits in development including mental retardation and im-
paired learning and memory, wherein DYRK1A is suggested to play a critical role (Ahn et al. 
2006). Almost all the patients with DS develop AD-like dementia and brain lesions similar to 
AD pathology by the age of 40, decades earlier than generally shown among population (e.g. 
Park et al. 2009). Besides tau, DYRK1A also phosphorylates amyloid precursor protein on 
threonine 668 and presenilin-1, which in turn could elevate the level of amyloid-! production 
and thereby senile plaque formation (Ryoo et al. 2008; Ryu et al. 2010). Considering these 
aspects, overexpression of DYRK1A has been suggested to have a crucial role in develop-
ment of AD pathology in DS and implicated as a functional link between AD and DS (Ryoo 
et al. 2007; Ryu et al. 2010). 
2.2.1.4 Fyn 
Unlike the kinases discussed so far, Fyn is a tyrosine kinase (Resh 1998). Fyn is a member of 
Src tyrosine kinase family with diverse biological functions, such as brain function regulation 
and cell adhesion signalling. Tyrosine phosphorylation of tau by Fyn has been reported to 
occur after amyloid-! exposure (Williamson et al. 2002) and during the development of neu-
rodegeneration, although it might not largely affect the microtubule-binding properties of tau 
(Lee et al. 2004). Regardless of its slight contribution to microtubule-binding efficacy of tau, 
tyrosine phosphorylation has been suggested to have distinct mechanisms to participate in the 
regulation of tau phosphorylation. Tyrosine phosphorylation may be an indicator of relocal-
ized tau towards cellular compartments where activated kinases are present, or, an indicator of 
activated src family kinases capable of activating the subsequent phosphorylation of tau by 
serine/threonine kinases. Regarding to the role of Fyn in neurodegeneration, it has been re-
cently suggested that axonal protein tau may have a role in Fyn transport in dendritic postsyn-
apse, thereby mediating the synaptotoxicity of A! via the N-methyl-D-aspartate (NMDA) 
receptor (Ittner et al. 2010).  
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2.2.1.5 PKA 
Protein kinase A (cAMP-dependent protein kinase, PKA) is a non-proline-directed multisub-
strate protein kinase, which participates in various pivotal signalling pathways (Walsh & Van 
Patten 1994). The elevated level of intracellular cAMP and the co-localization of the PKA 
holoenzyme and the specific substrates, are the key regulatory elements on inducing the acti-
vation of PKA-catalyzed signal transduction pathway. The role of PKA on tau phosphoryla-
tion, like numerous other kinases, has been widely studied in vitro, and also, the function of 
PKA on tau phosphorylation has been presented in vivo (Liu, S.J. et al. 2004).  
 PKA is a priming kinase that prephosphorylates its substrates (e.g. tau) at specific ser-
ine/threonine sites and, thereby, facilitates the subsequent phosphorylation by GSK-3 or 
CDK-5, or both (Liu, S.J. et al. 2004; Wang et al. 2007). Furthermore, it has been suggested 
that contribution of PKA alone, preceeding the sequental phosphorylation by various kinases, 
may generate AD-like abnormal phosphorylation state of tau in a duration-independent man-
ner (i.e. only transitory activation with specific PKA-activator could induce tau hyperphos-
phorylation) (Zhang et al. 2006; Wang et al. 2007). Besides PKA, other non-proline-directed 
protein kinases, such as calcium- and calmodulin-dependent protein kinase II (CaMKII), pro-
tein kinase C (PKC) and casein kinases, have been indicated to play roles in the regulation of 
tau hyperphosphorylation (e.g. Kuret et al. 1997; Yamamoto et al. 2002; Liu et al. 2003). 
2.2.1.6 MAP kinases 
Mitogen-activated protein kinases (MAPKs) are a family of proline-directed serine/threonine 
protein kinases that have been extensively studied (e.g. Schaeffer & Weber 1999). MAPK 
signal trasduction cascades participate in many cellular functions and typically function in a 
signal cascade involving at least three consecutive kinases (e.g. MAP3K, MAP2K and 
MAPK) (Schaeffer & Weber 1999; Kim & Choi 2010). The subsequent activation of the 
kinases in the signalling pathway eventually leads to phosphorylation of numerous MAPK 
substrates. The activation of these signalling pathways may occur through interaction between 
two components of the kinase or due to a result of multiple kinase signalling complex forma-
tion regulated by specific proteins (Kim & Choi 2010). 
 The family of mammalian MAPK includes extracellular signal-regulated kinase (ERK), c-
Jun NH2-terminal kinase (JNK, which is also known as stress activated protein kinase) and 
p38 (Schaeffer & Weber 1999). All of these kinases exists in various isoforms (e.g. ERK1 to 
ERK8) and take part in numerous cellular programs, such as apoptosis, inflammation and 
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other stress responses, and cell growth and differentiation. The contribution of MAPK signal-
ling pathways to pathogenesis of wide array of disorders, consisting cancer and many neu-
rodegenerative disorders like AD, Parkinson’s disease (PD) and amyotrophic lateral sclerosis 
(ALS), have been established (e.g. Kim & Choi 2010). 
 In AD, the MAPKs have been implicated to have multiple distinct roles in disease patho-
genesis, including the regulation of !- and $-secretases, the induction of neuronal apoptosis 
and phosphorylation of both AD hallmark proteins, APP and tau (e.g. Munoz & Ammit 2010; 
Kim & Choi 2010). JNK, ERK and p38 MAPK have each been suggested to participate in 
aberrant tau phosphorylation in AD (e.g. Churcher 2006). Activated (phosphorylated) p38 has 
been shown to co-localize with accumulated tau in cortical and hippocampal brain slices of 
patients with AD (Zhu et al. 2000) and also in transgenic htau mice (Kelleher et al. 2007). The 
finding that microglial interleukin-1 (IL-1), a cytokine known to activate p38 MAPK, acti-
vates p38 in neurons, which in turn may lead to a neurofibrillary degeneration through in-
creased tau phosphorylation, is suggested to provide a molecular link between neuroinflam-
mation and tau hyperphosphorylation (Sheng et al. 2001). 
2.2.2 Dephosphorylation 
Protein phosphatases (PP) reverse the tau phosphorylation by kinases (Liu et al. 2005). The 
activity of PPs is regulated via various cellular mechanisms including calcium, subcellular 
localization of the PPs and its substrates and phosphorylation of the PP-subunits (Tian & 
Wang 2002). There are five serine/threonine PPs found to be expressed in the mammalian 
brains: PP1, PP2A, PP2B, PP2C and PP5, from which all except PP2C is known to dephos-
phorylate tau protein in vitro (Liu et al. 2005). PP1, PP2A, PP2B and PP5 all dephosphorylate 
the same specific tau phosphorylation sites, but the efficacy towards different sites differs 
largely (table 1). In the human brain, the total tau dephosphorylation activity of protein phos-
phateses 1, 2A, 2B and 5 is unevenly distributed; ~11%, ~71%, ~7% and ~ 10%, respectively. 
These partial PP contributions, in addition to the findings of decreased activity of PP2A in 
human AD brains, suggest PP2A to be the major tau phosphatase. PP2A regulates the phos-
phorylation not only by dephosphorylating tau, but it also regulates the kinases that participate 
in the phosphorylation of tau (Tanimukai et al. 2005). 
 Two distinct endogenous inhibitors, I1PP2A and I2PP2A, regulate the intracellular activity of 
PP2A (Tanimukai et al. 2005). I1PP2A inhibit PP2A through its catalytic subunit (PP2Ac), un-
like I2PP2A, which is first cleaved into two fragments and translocated from nucleus to cyto-
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plasm, where it interacts with PP2Ac and co-localizes with aggregated tau. The level of these 
two heat-stable proteins have been found to be increased ~20% in the AD brains and have an 
effect on abnormal tau hyperphosphorylation. Memantine, which is an NMDA-receptor an-
tagonist clinically used to treat AD, has been reported to restore the ability of PP2A to 
dephosphorylate tau and to inhibit abnormal tau phosphorylation and neurofibrillar degenera-
tion (Li et al. 2004).  
The activity and the expression level of PP2A are notably reduced in the AD brain, which 
is indicated to contribute to tau hyperphosphorylation (e.g. Vogelsberg-Ragaglia et al. 2001). 
Taken together the reduced levels, the suggested role as the major tau phosphatase and inter-
action with other AD-related proteins, PP2A is considered as a potential target for drug de-
velopment for AD (e.g. Tian & Wang 2002; Liu et al. 2005). Furthermore, an increase in de-
methylation of PP2A disrupts the regulation of its activity and may decrease the dephosphory-
lation of hyperphosphorylated tau, thus augmenting the importance to further studies PP2A 
function in AD (Zhou et al. 2008). Recently, it has been implicated that sodium selenate is a 
specific PP2A activator, a compound shown to reduce tau phosphorylation without any signs 
of neurotoxicity (Corcoran et al. 2010; van Eersel et al. 2010). Sodium selenate has been re-
ported to markedly enhance the PP2A activity and stabilize the PP2A-tau complex, hereby 
providing a promising novel candidate to targeted AD treatment. 
 
Table 1. The specific sites of tau phosphorylated and dephosphorylated by certain kinases and 
phosphatases. N-tau, tau from normal adult brain; AD-tau, abnormally hyperphosphorylated 
tau from Alzheimer’s disease brains; CaMKII, calcium- and calmodulin-dependent protein 
kinase II; CDK5, Cyclin-dependent kinase 5; ERK 1/2, extracellular signal-regulated kinase; 
GSK-3!, Glycogen synthase kinase-3!; PKA, cyclic AMP-dependent protein kinase; 
PP1/PP2A/PP2B/PP5, protein phosphatase 1/2A/2B/5; T, threonine; S, serine; Y, tyrosine. 
 
Kinases Phosphatases 
Site N-tau 
AD-
tau CaMKII CDK5 ERK 1/2 
GSK-
3!  PKA FYN PP1 PP2A PP2B PP5 
T39  X           
S46  X   X X    X X  
T50     X X       
S131   X          
T135   X          
T149      X       
T153  X   X X       
T175  X    X       
T181 X X  X X X    X X X 
S184      X       
S195    X  X       
S198  X    X X      
S199 X X  X X X   X X X X 
S202 X X  X X X   X X X X 
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T205 X X  X X X   X X X X 
S208  X    X X      
S210  X    X X      
T212 X X X X X X   X X X X 
S214 X X X    X  X X X X 
T217  X  X X X X  X X X  
T220      X X      
T231  X  X  X   X X X X 
S235  X  X X X   X X X X 
S237  X    X       
S238  X           
S241  X    X       
T245      X X      
S258      X X      
S262  X X   X X  X X X X 
S285  X    X       
S289      X       
S305  X    X X      
S324  X    X X      
S352  X    X X      
S356  X X   X X   X X  
T373    X  X       
S396 X X  X X X   X X X X 
S400  X    X       
T403  X    X       
S404 X X  X X X   X X X X 
S409  X    X X  X X X X 
S412  X    X X      
S413  X    X X  X    
T414      X X      
S416  X X   X X      
S422  X   X     X X  
Y18  X      X     
Y29  X      X     
Y394  X      X     
2.2.3 Hyperphosphorylation and mechanism of neurofibrillary degeneration 
Abnormal hyperphosphorylation of tau is the major factor contributing to tau dysfunction and 
neurofibrillar degeneration in AD and other related tauopathies (e.g. Grundke-Iqbal et al. 
1986; Alonso et al. 1994; Iqbal et al. 2009). In contrast to normally phosphorylated tau con-
taining 2-3 moles of phospahate per mole of tau, the phosphorylation status of hyperphos-
phorylated tau is 3-4 fold higher in AD brains (Kopke et al. 1993). Numerous factors, includ-
ing impairment of the phosphorylation/dephosphorylation equilibrium, alterations in brain 
glucose metabolism and pathways mediated by A! (although there are controversies about the 
role of A!), are a few to mention that may induce the abnormal hyperphosphorylation of tau 
(e.g. Gong & Iqbal 2008). Regardless of extensive studies, the mechanism of hyperphos-
phorylated tau-induced neurofibrillar degeneration is not completely understood but probably 
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involves both loss of normal function and gain of toxic function components (e.g. Wang & 
Liu 2008). 
 Most likely due to abnormal hyperphosphorylation, tau detaches from the microtubules and 
is accumulated into intraneuronal tangle formations of paired helical filaments (PHF) and or 
straight filaments (SF), wherein it is the predominant protein subunit, and, which subse-
quently forms neurofibrillary tangles (NFT) (Grundke-Iqbal et al. 1986; Iqbal et al. 1989; 
Alonso et al. 2001a). In addition to self-assembly of all of the six tau isoforms into inert ag-
gregates of PHFs/NFTs (Alonso et al. 2001a), the non-fibrillized cytosolic hyperphosphory-
lated tau also sequesters other microtubule-associated proteins (MAP1 and MAP2) and nor-
mal tau (Kopke et al. 1993; Alonso et al. 1994; Alonso et al. 1997). This toxic gain-of-
function leads to inhibition of microtubule assembly and disruption in microtubule stabiliza-
tion. AD-like hyperphosphorylated tau (AD-like p-tau) binds to and sequesters different tau 
isoforms with affinity of 2N/4R > 1N/4R > 0N/4R and 2N/3R > 1N/3R > 0N/3R, and also 
that 2N/4R > 2N/3R (Alonso et al. 2001b). According to the preferential sequestration of 4R-
tau isoforms by AD-like p-tau, the absence of N-terminal inserts and the additional fourth 
microtubulebinding repeat (R2) in fetal tau isoform (0N/3R), implicates a protective role for 
fetal human tau from neurofibrillary degeneration. AD-like p-tau is also suggested to decrease 
the function of proteasomes and the PHF-tau has been found to be polyubiquitynated, which 
raises the question on the importance of the degradation and clearence of AD-like p-tau 
(Cripps et al. 2006). Furthermore, hyperphosphorylated tau compromises axonal transport by 
interfering with the kinesin-like motor proteins and by destabilizing microtubules, which 
serve as tracks in axonal transport of various organelles and proteins (e.g. Tatebayashi et al. 
2004).  
 The role of protein kinases and different combinations of these kinases that can induce the 
abnormal phosphorylation of tau, have been established (Wang et al. 2007). By phosphorylat-
ing tau with various kinases, including PKA, CaMKII, GSK-3! and CDK-5, using diverse 
subsequental kinase treatments, normal tau was shown to hyperphosphorylate, and self-
assembly into PHFs was induced. The ability of PP2A to dephosphorylate all the crucial sites 
needed for AD-like p-tau self assembly, was also reported, thereby augmenting its role as the 
major tau dephosphorylating protein phosphatase. Additionally, the rephosphorylation of 
PP2A-dephosphorylated AD-like p-tau by different kinase combinations restored the proper-
ties to form PHFs/NFTs, implicating that abnormal tau hyperphosphorylation is reversible 
event and requires more than one protein kinase. 
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 The sequential pattern of various AD-associated phosphorylation sites has been studied in 
vitro (Bertrand et al. 2010). Besides the priming effects of different kinases, the sequential 
phosphorylation of specific tau sites could also regulate the overall phosphorylation status of 
tau via various cascades. The AT8 epitope (Ser199, Ser202, Thr205) is suggested as a central 
regulator of cascades that modulate the priming and feedback processes.  
2.3 Other molecules interacting with tau 
2.3.1 !-Tubulin 
Microtubules (MTs) are essential elements in numerous vital functions including cell motility, 
cell division and cell morphology (e.g. Chau et al. 1998). These functions are regulated by 
microtubule-associated proteins (MAPs) by stabilizing the MT structure and promoting their 
dynamics. MTs are non-covalent cytoskeletal tubulin polymers, which are unstable unless 
stabilized by other molecules (e.g. Kar et al. 2003). These polarized tubulin structures are 
assembled from #- and !-tubulin monomer subunits forming a heterodimer. 
 MAP tau binds to !-tubulin subunits within the microtubule through its repeat-region se-
quences located in the MBD (Lee et al. 1989; Chau et al. 1998; Amos 2004). Upon abnormal 
hyperphosphorylation, tau loses its function to regulate MT-dynamics leading to disruption of 
MT-network and impaired axonal transport in AD brain. In addition to tau, !-tubulin, more 
specificly !-III-tubulin isoform, which is the predominant form of tubulin in neurons, can also 
be hyperphosphorylated in AD (Vijayan et al. 2001). The decreased PP2A activity in AD 
brain, which has been also associated with microtubules, reduces tau dephosphorylation and is 
also suggested to play a part in abnormal phosphorylation of !-tubulin. Although the hyper-
phosphorylation of !-tubulin may not have a significant impact on MT assembly in young 
healthy human brain, in AD the contribution of hyperphosphorylated !-tubulin might be 
noteworthy due to a disturbed tau-related regulation of phosphorylation and MT assembly.  
2.3.2 14-3-3" 
The 14-3-3 family of acidic proteins are regulatory molecules with ability to bind vast array 
of signalling proteins (Fu et al. 2000). 14-3-3 participates in various cellular processes by 
binding to its target proteins and thereby regulating and stabilizing enzyme activity and con-
formation, and, mediates protein-protein interactions and subcellular localization of proteins. 
Due to the large number of target binding proteins, as an abundant brain protein, 14-3-3 plays 
a substansial role in many regulatory functions such as cell cycle control, apoptosis and signal 
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transduction (Fu et al. 2000; van Hemert et al. 2001). To date, seven different isoforms of 14-
3-3 is characterized (!, %, $, &, ', ( and "), which are all encoded by distinct genes and are 
expressed in all eukaryotes. These highly conserved phosphoserine-binding proteins largely 
exist as dimers, with a molecular mass approximately of 30 kDa per subunit (van Hemert et 
al. 2001; Yuan et al. 2004). Each monomer subunit consists of 9 antiparellel #-helices form-
ing an amphipathic groove that mediates its binding to phosphoserine residues. The regulation 
of interaction of 14-3-3 with its ligands is highly controlled by diverse mechanisms, such as 
post-translational modifications, the expression level within the cell and the specifity of dif-
ferent isoforms (Fu et al. 2000). 
 The phosphorylation status of Ser58 of 14-3-3", which is located within the interface of the 
dimer, determines whether the 14-3-3" is in monomeric or dimeric structure (Woodcock et al. 
2003). When phosphorylated at Ser58, 14-3-3" is reported to solely exist as a monomer, sug-
gesting that the stability of the dimeric structure is sufficiently disrupted by the phosphoryla-
tion of single monomer both in vitro and in vivo. This specific site has been shown shown to 
be phosphorylated by protein kinases, such as Akt in vitro (Powell et al. 2002) and sphingos-
ine-dependent kinase in vitro and in vivo (Woodcock et al. 2003). Although the cellular func-
tion of 14-3-3" is highly facilitated by its dimeric structure, the phophorylation-mediated dis-
ruption of the dimer does not inhibit its ability to bind the target proteins indicating a role in 
substrate activity regulator.      
 14-3-3 has been strongly indicated to interact with multiple molecules participating in 
pathways affecting abnormal tau phosphorylation (e.g. Agarwal-Mawal et al. 2003; Hernan-
dez et al. 2004; Kim et al. 2004). Tau, GSK-3! and 14-3-3" were reported to be components 
of a multiprotein complex associated in tau phoshorylation (Agarwal-Mawal et al. 2003). 
These components have been found to co-immunoprecipitate from brain extracts. The mecha-
nism how 14-3-3" connects GSK-3! to tau within the complex remains to be eluciated, but it 
is suggested that 14-3-3" mediates Ser9-phosphorylated GSK-3! and tau interaction, although 
the interaction between Ser9-GSK-3! and 14-3-3" seems to be tau-independent (Yuan et al. 
2004). Hence, 14-3-3" facilitates the binding of Ser9-GSK-3! to tau and stimulates the phos-
phorylation of tau by GSK-3!. Additionally, the phosphorylation of tau at Ser214 residue by 
Akt kinase is reported to highly increase the affinity of 14-3-3" towards tau and thereby di-
minish, or even abolish its aggregation and fibril formation (Sadik et al. 2009). 
 Upstream of GSK-3!-catalyzed tau phosphorylation, the role of 14-3-3" regulating the 
PKA-mediated phosphorylation of tau has been studied (Hashiguchi et al. 2000; Hernandez et 
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al. 2004). It has been hypothized that, due to a same binding region in tau and under specific 
conditions, there may be competion between 14-3-3" and tubulin to bind to tau (Hashiguchi et 
al. 2000). The presence of PKA is shown to reduce the polymerization of tau, due to a pres-
ence of 14-3-3", which can facilitate tau phosphorylation and should threfore have decreased 
ability to form aggregates (Hashiguchi et al. 2000; Hernandez et al. 2004). These results im-
plicate a protecting role of PKA conserning aggregation of tau into fibrillar filaments. There 
are also findings reporting 14-3-3" to increase the activity of DYRK1A, a kinase associated to 
both AD and DS, through mediating the stability of active structure of 14-3-3" (Kim et al. 
2004). The binding of 14-3-3" to DYRK1A is implicated to be independent of the phosphory-
lation state of DYRK1A, and, the activation of DYRK1A is suggested to occur in dose-
dependent manner in vitro.  
2.3.3 Pin1  
Peptidyl-prolyl isomerases (PPIases) act as a conformatial switch that catalyzes the cis/trans 
isomerization of peptidyl-prolyl peptide bonds (figure 2) (e.g. Yaffe 1997; Zhou et al. 1999). 
There are three highly conserved PPIase-families, cyclophilins, FK506 binding proteins 
(FKBPs) and parvulins (Lu et al. 1996; Lu, K.P. et al. 2002). Although Pin1 belongs to the 
subfamily of parvulin PPIases, it is the only PPIase that specifically recognizes and isomer-
izes phosphorylated serine/threonine-proline sequences (pSer/Thr-Pro) (Yaffe 1997).  
 Pin1 (protein interacting with NIMA (never in mitosis A) 1) is a ubiquitous enzyme with a 
high phosphoprotein substrate specifity (e.g. Zhou et al. 1999). Pin1 contains two distinct 
structural domains; the phosphorylation specific amino-terminal WW domain, which modu-
lates the binding of Pin1 to its substrates, and, the carboxy-terminal PPIase-domain that cata-
lyzes the conformational isomerization of bound substrates (Lu et al. 1996; Yaffe 1997; Lu, 
K.P. et al. 2002). One of the regulatory mechanisms of Pin1 includes the phosphorylation of 
Ser16, which is located at pSer/Thr-Pro-binding pocket of Pin1 protein (Lu, P.J. et al. 2002). 
Ser16 phosphorylation prevents the interaction between WW domain and pSer/Thr-Pro motif, 
thereby regulating the substrate binding activity. Furthermore, the subcellular localization 
regulates Pin1 function. The localization of Pin1 within a cell depends on its substrate avail-
ability, and in order to bind with a substrate, the interaction with WW domain is required. 
Hence, the subcellular localization is also dependent on the phosphorylation state of Ser16 of 
pSer/Thr-Pro motif. Additionally, the expression level of Pin1 regulates its function, which is 
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normally driven by cell division cycle (e.g. Liou et al. 2002), with an exception in neurons, 
where the Pin1 level is increased (Lu et al. 1999). 
 
 
 
 
Figure 2. Peptidyl-prolyl cis/trans isomerization. The unique property of proline residues to 
exist in two completely distinct isoforms can potentially provide a switch in the backbone of 
polypeptide chain (a). This peptidyl-prolyl bond switch is controlled by cis/trans isomeriza-
tion. The spontaneous conversion between the two isomers within peptides is intrinsically a 
slow process. To avoid these possible rate limitations in protein folding and refolding caused 
by rather slow spontaneous cis/trans isomerization, the conversion is catalyzed by ubiquitous 
peptidyl-prolyl cis/trans isomerases (PPIases).  PPIase enzymes are divided in three families; 
cyclophilins, FK506 binding proteins (FKBPs) and parvulins, which is further divided into 
subfamilies of parvulin-type and Pin1-type PPIases based on their substrate specifity. Impor-
tantly, phopsphorylation of serine/threonine-proline (Ser/Thr-Pro) motifs, which are the major 
regulatory phosphorylation motifs in the cell, hinders the catalytic action of cyclophilins, 
FKBPs and parvulin-type PPIases toward these bonds. By contrast, Pin1 and Pin1-type PPI-
ases specifically isomerize phosphorylated Ser/Thr-Pro bonds (b). Isomerization of both 
phosphorylated and nonphosphorylated Ser/Thr-Pro motifs is highly important due to a con-
formatial specifity of numerous protein kinases and phosphatases, which phosphorylate and 
dephosphorylate mostly the trans-form of proline bond of proteins. S; serine, P; proline 
(modified from Lu, K.P. et al. 2002). 
 
 Pin1 regulates various cellular processes, due to, at least partially, its wide array of sub-
strates (e.g. Lu, K.P. et al. 2002). These processes include the regulation of cell cycle progres-
sion and cellular signalling, modulation of transcription and RNA processing, and, participat-
ing in neuronal survival and in responses to DNA damage and cellular stress (e.g. Lu, K.P. et 
al. 2002; Lu 2004). Under the normal physiological conditions, Pin1 is highly regulated and 
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the deregulation has been associated with various human diseases, mostly in cancer and AD 
(e.g. Lu 2004). The finding that Pin1 specifically recognizes and catalyzes the isomerization 
of pSer/Thr-Pro bonds, which subsequently leads to conformational changes in such motifs in 
proteins, provided a novel mechanism in post-phosphorylational protein signalling and modi-
fication (Ranganathan et al. 1997; Yaffe 1997; Lu 2004). 
 AD hallmark proteins, APP and tau, are both modified by peptidyl-prolyl cis/trans 
isomerase Pin1 (Liou et al. 2003). In the case of APP, it has been suggested that cis conforma-
tion of phosphorylated Thr668-Pro residue may promote the amyloidogenic processing of 
APP leading to A! formation, and in contrast, trans conformation favours the non-
amyloidogenic pathway (Pastorino et al. 2006). By catalyzing the conversion from cis to trans 
conformation, Pin1 facilitates the non-amyloidogenic APP processing, thereby reducing the 
A! and plaque formation. Interestingly, the amyloidogenic APP processing is reduced by 
Pin1 mediated GSK-3! inhibition (Ma et al. 2012). By binding to phosphorylated Thr330-Pro 
motif in GSK-3!, Pin1 inhibits the kinase activity resulting in decreased phosphorylation of 
Thr668 by GSK-3! and increased turnover of APP. The inhibition of kinase activity by func-
tional Pin1 is reported to occur both in vitro and in vivo using stable GSK-3! knockdown H4 
cells and Pin1-WT, -KO and –Tg mice. Hence, by reducing the total APP levels via increased 
protein turnover, GSK-3! inhibition by Pin1 provides a novel mechanism to mitigate A!-
driven AD pathology. 
 Pin1 binds to and isomerizes tau at phosphorylated Thr231-Pro motif (figure 3) (Lu et al. 
1999). Proline-directed PP2A is a conformation-specific phosphatase interacting only with the 
trans isomeric form of pSer/Thr-Pro motif (Zhou et al. 2000). Hence, by catalyzing the con-
version from cis to trans isomer, Pin1 facilitates the dephosphorylation of tau by PP2A and 
may restore the ability of tau to bind and stabilize microtubules (Lu et al. 1999; Zhou et al. 
2000). Depletion of Pin1, or its decreased activity as seen in AD, induces the cis isomer of 
pThr231-Pro motif to accumulate, leading to increased tau hyperphosphorylation and forma-
tion of neurofibrillary tangles. In addition, the dephosphorylation on Ser16 residue of Pin1 
and simultaneous dephosphorylation of tau at Thr231 residue, is suggested to be induced by 
A! (1-42) treatments in hippocampal neurons (Bulbarelli et al. 2009). These results suggest 
that tau hyperphosphorylation may be reduced or prevented due to an A! (1-42) induced Pin1 
function. Taken together, Pin1 has an essential role in protection against age-dependent neu-
rodegeneration and provide a noteworthy candidate to targeted AD treatment (e.g. Liou et al. 
2003). 
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Figure 3. Pin1 catalyzed cis/trans isomerization of Proline-directed pThr231-tau in Alz-
heimer’s disease. Phosphorylated threonine 231 residue in tau can adopt into two completely 
distinct conformations (cis and trans), a conversion catalyzed by Pin1 between the two con-
formations. Pathogenic cis-form may result in loss of normal microtubule stabilizing function 
of tau and further induce toxic gain-of-function. Acting as a conformatial switch by convert-
ing pThr231-tau from pathogenic to nonpathogenic conformation, Pin1 prevents the accumu-
lation of the more stable cis form. This may subsequently restore the normal tau functions 
such as proper subcellular localization and decrease aggregation, and promote the dephos-
phorylation of tau in Alzheimer’s disease. MCI; mild cognitive imparment (modified from 
Nakamura et al. 2012). 
2.4 Other post-translational modifications 
Besides phosphorylation, tau protein can be post-translationally modified through various 
mechanisms (e.g. Gong et al. 2005). These modifications include glycosylation, glycation, 
ubiquitination, polyamination, truncation, nitration (Gong et al. 2005) and acetylation (Min et 
al. 2010). Both, under the normal and under the pathological conditions, these post-
translational modifications plays a pivotal role in converting the normal functional tau to-
wards PHF/SF- formation and subsequent neurofibrillar degeneration in AD and related 
tauopathies (Gong et al. 2005; Wang & Liu 2008). 
 In glycosylation, oligosaccharides are covalently linked to protein side chains, in a reaction 
that is facilitated by various enzymes such as glycotransferases (Gong et al. 2005; Wang & 
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Liu 2008). Depending on the form of the glycosidic bond, two distinct glycosylation types 
have been identified: O-linked and N-linked glycosylation. N-glycolysation defines a reac-
tion, in which the oligosaccharides are covalently linked to the amino groups of asparagine 
side chains. Protein N-glycosylation normally takes place in rough endoplastic reticulum and 
Golgi apparatus (e.g. Gong et al. 2005), and is enhanced in PHF-tau in comparison to normal 
functioning tau (Liu et al. 2002b). It has been reported that abnormal glycosylation promotes 
tau hyperphosphorylation by activating phophorylation via specific kinase pathways (e.g. 
PKA, GSK-3! and CDK-5) and by inhibiting dephosphorylation by PP2A and PP5 (Liu et al. 
2002a). Additionally, the effects of glycosylation on phosphorylation are site-specific, and, 
aberrant glycosylation precedes abnormal tau hyperphosphorylation (Liu et al. 2002a; Gong et 
al. 2005). 
 In O-glycosylation, oligosaccharides are added to serine or threonine residues of hydroxyl 
groups that are in close proximity of proline residues (Gong et al. 2005; Wang & Liu 2008). 
Especially, the addition of O-linked monosaccharide !-N-acetylglucosamine (O-GlcNAc) to 
serine/threonine residues of tau has been studied (Arnold et al. 1996; Liu, F. et al. 2004). O-
GlcNAcylation has been found to be decreased in AD brains, which is at least partially due to 
the observation, that O-GlcNAcylation occurs in same serinene/threonine sites with phos-
phorylation in tau (Liu, F. et al. 2004). Moreover, an impaired brain glucose metabolism 
negatively regulates O-GlcNAcylation, which may lead to consequent hyperphosphorylation 
of tau. Although the glycosylation is one of the most common post-translational modifications 
of tau, the molecular mechanism(s) is yet to be determined (Gong et al. 2005). However, the 
down-regulation of O-GlcNAcylation provides one mechanism by which defective brain glu-
cose metabolism is linked to development of AD.  
In a very recent study, it was shown that chemical inhibition of glycoside hydrolase (O-
GlcNAcase), which removes the O-GlcNac from the Ser/Thr residues, increased the amount 
of O-GlcNAc and effectively slowed the loss of motor neurons in vivo (Yuzwa et al. 2012). 
The O-GlcNAcase was inhibited in JNPL3 mice, a transgenic mouse model that expresses 
human FTDP-17 tau P301L mutant transgene and develops neurofibrillary tangles, using 
Thiamet-G as an inhibitor and resulted in decreasing number of NFTs compared to vehicle 
treatments. Interestingly, the modification of O-GlcNAcylation did not alter the phosphoryla-
tion status of the sites studied in vitro, which suggests that the mechanism is completely 
phosphorylation-independent. By using various tau mutants, the O-GlcNAcylation of Ser400 
residue was reported to play a major role in decreased tau fibrillization. Furthermore, no ap-
parent adverse side effects were reported in these mice over a treatment period of 8 months. 
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Importantly, the protective effect of O-GlcNAcylation against protein aggregation does not 
seem to be only specific for tau, but also could hinder the aggregation and promote the stabil-
ity of totally unrelated proteins. Hence, the modification of O-GlcNAcylation could provide a 
novel candidate for therapies for tauopathies and preventing the aggregation of unrelated pro-
teins and stabilize their cellular function.   
 Different from enzymatic glycosylation, glycation denotes non-enzymatic linkage of re-
ducing saccharides to amino side chains of polypeptides (Yan et al. 1994; Gong et al. 2005). 
Advanced glycation end products (AGE) are heterogenous formations of subsequent oxida-
tion of protein glycation, which are shown to be present in PHFs/NFTs (Yan et al. 1994; Sa-
saki et al. 1998). Furthermore, tau glycation was shown to induce neuronal oxidative stress 
(Yan et al. 1994) and has also been suggested to facilitate the formation of PHFs (Kuhla et al. 
2007).  
 Unlike normal tau and soluble abnormally hyperphosphorylated tau, PHF-tau and NFTs 
are polyubiquitinated in AD (Perry et al. 1987). Misfolded or damaged proteins under normal 
conditions are ubiquitin-labelled and degraded by the ubiquitin-proteasome pathway in an 
ATP-dependent manner (e.g. Gong et al. 2005). However, the degradation of polyubiquiti-
nated PHF-tau is highly reduced in AD brains, which may be due to an impaired proteasome 
function, leading to concurrent aggregation of tau and to formation of NFTs (Keller et al. 
2000). Additionally, another modification affecting the degradation rate of tau is polyamina-
tion (Tucholski et al. 1999). Results from in situ studies suggests that the addition of poly-
amines to tau in a reaction catalyzed by tissue transglutamase, does not largely compromise 
its microtubule binding affinity, but exacerbates the calcium-induced degradation by calpain 
protease. 
 The C-terminal truncation of tau by caspase and other proteases changes the conformation 
of tau and, compared to normal full-lenght form, cleaved tau is more prone to aggregate into 
PHFs/NFTs (Yin & Kuret 2006). Truncation of tau is suggested to occur at early stages of 
disease development of AD, and also, that it can induce the tau fibrillization even in low con-
centrations, i.e. the critical consentration is lowered due to C-terminal tau truncation. 
 The nitration of tau has been reported to contribute to tau filament formation and it has 
been shown to co-localize with NFTs in AD (Horiguchi et al. 2003). This post-translational 
modification of tau is site-specific towards tyrosine residues Tyr18, Tyr29, Tyr197 and 
Tyr394 (Reynolds et al. 2005), from which Tyr29-nitrated tau is reported the most affected in 
AD brains, and therefore suggested to have an impact on AD progression (Reynolds et al. 
2006). Furthermore, it has been recently reported that tau is acetylated, and, that acetylation of 
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tau prevents the ubiquitin-mediated degradation of abnormally hyperphosphorylated tau (Min 
et al. 2010). This study suggests the role of histone acetyltransferase p300 as a promoter of 
tau acetylation, and in contrast, a protein deacetylase SIRT1 to induce the deacetylation. 
Moreover, SIRT1 deprivation is suggested to promote tau hyperacetylation, which may result 
in abnormal hyperphosphorylation and neurofibrillar degeneration. This effect was shown to 
be reversed by inducing the deacetylation of tau. 
 After the reversible acetylation of tau emerged as a novel post-translational modification, 
its molecular mechanism and significance on tau function in AD and other neurodegenerative 
tauopathies has been of interest in multiple studies. Interestingly, the lysine residue 280 
(K280) within a microtubule-binding region of tau pointed out to be the major target site of 
acetylation and it may have a pathological role in AD and other tauopathies (Cohen et al. 
2011). Due to its localization within the microtubule-binding motif, acetylated K280 residue 
disrupts the normal tau function by preventing its binding to MTs resulting in decreased MT-
assembly and stability (Cohen et al. 2011; Irwin et al. 2012). In addition to loss of normal tau 
functions, toxic gain of functions such as increased tau fibrillization and increased amount of 
soluble tau prone to oligomerization to PHFs uniformly contribute to tau-driven neurodegen-
eration. Thereby, inhibition of acetylation of tau K280 could offer a novel candidate for drug 
discovery for tauopathies. Nevertheless, the connection between phosphorylation and acetyla-
tion in specifically identified multiple sites and their dynamics and effects on tau oligomeriza-
tion need to be further investigated to fully understand the synergism of these post-
translational modifications.   
2.5 Role of tau in central nervous system disorders 
Abnormally hyperphosphorylated tau is the predominant protein subunit forming PHFs/SFs in 
Alzheimer’s disease brain (e.g. Grundke-Iqbal et al. 1986; Iqbal et al. 1989). The subsequent 
formation of neurofibrillary tangles is the second neuropathological hallmark lesion of AD in 
addition to amyloid plaques. It has been established that the NFTs in AD, and not the A! 
plaques, are the lesions that correlates with the severity of cognitive decline and dementia 
(e.g. Buee et al. 2000; Wang & Liu 2008). It seems that amyloid plaque pathology precedes 
NFT pathology in AD. Regardless of AD being the most common and the most studied spo-
radic tauopathy, it is not fully understood how abnormally hyperphosphorylated tau and the 
formation of filaments affect on the learning impairment and memory deficits. 
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The aggregation of abnormally hyperphosphorylated tau is not specific to AD, but has been 
described in several other neurodegenerative disorders referred as tauopathies (table 2) (e.g. 
Buee et al. 2000; Iqbal et al. 2005). The development of each of these tauopathies involves 
neurofibrillary degeneration associated with dementia, which is induced by aberrant accumu-
lation of hyperphosphorylated tau. The mechanisms that may promote the alterations in tau 
metabolism includes missense mutations, various post-translational modifications such as 
phosphorylation and glycosylation, altered expression of different tau isoforms or the amount 
of total tau expression (e.g. Hernandez & Avila 2007). The discoveries of several tau gene 
missense mutations that co-segregate with the disease in Frontotemporal dementia with park-
insonism linked to chromosome 17 (FTDP-17), implicates that tau abnormalities per se are 
disease-causative and could lead to neurofibrillary degeneration (e.g. Hutton et al. 1998; Spil-
lantini et al. 1998). These findings together with the notified absence of tau mutations in AD, 
emphasizes the critical role of tau in AD pathogenesis and that tau abnormalities can directly 
be disease-causative (e.g. Brunden et al. 2008).  
In FTDP-17, one of four known tau missense mutations (G272V, P301L, V337M and 
R406W) results in tau forms that are in vitro better substrates to be phosphorylated by various 
protein kinases in the brain compared to wild-type human tau (Alonso Adel et al. 2004). 
Moreover, these mutated tau proteins are more rapidly and with higher extent hyperphos-
phorylated than 4R-taus, which in contrast hyperphosphorylates faster than 3R-tau species. 
The self-aggregation of mutated tau species requires 4-6 moles of phosphate per mole of tau 
to form filaments, whereas )10 moles of phosphate per mole of protein is required in the case 
of wild-type tau to polymerize. The conformational change in tau induced by these missense 
mutations, besides making it more prone to hyperphosphorylation, also promote the seques-
tration of normal tau, which could further explain the severity and autosomal dominance of 
inherited FTDP-17. To date, 32 different mutations including missense, deletion, silent and 
intronic mutations have been described in more than 100 FTDP-17-families (Goedert & Jakes 
2005). From these mutations, approximately half contributes to increased abnormal filament 
formation of tau and its reduced ability to interact and bind to microtubules. The other half of 
the mutations affects the RNA level of tau by disrupting the normal 4R/3R-ratio that has been 
observed in various neurodegenerative disorders. 
Normally the ratio of 4R-tau to 3R-tau isoforms in healthy human brain is approximately 1 
(Hong 1998). In FTDP-17, the ratio of 4R/3R is dramatically increased mainly due to the al-
ternative splicing of exon 10 induced by intronic mutations (e.g. Hutton et al. 1998; Spil-
lantini et al. 1998). The findings that neurofibrillay tangles isolated from affected areas of AD 
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brain shows increased amount of 4R-tau (e.g. Glatz et al. 2006), and, that the 4R-tau is the 
predominant isoform in tau polymers in FTDP-17 (e.g. Hong 1998), may at least partially 
explain why the increase in 4R/3R ratio can cause neurofibrillary degeneration (e.g. Iqbal et 
al. 2005; Wang & Liu 2008). On the contrary, in Pick’s disease and Down syndrome, both 
characterized by early onset dementia, 3R-tau (lacking exon 10) is the major isoform ex-
pressed (Yoshida 2006; Shi et al. 2008). Therefore, according to the contradictive manifesta-
tions of both 4R-tau and 3R-tau in various neurodegenerative diseases, it seems that it is more 
likely the altered ratio of these isoforms rather than the toxicity of each tau isoform per se that 
is promoting neurofibrillary degeneration in tauopathies (e.g. Wang & Liu 2008).  
 
Table 2. Neurodegenerative tauopathies involving abnormally hyperphosphorylated tau. In 
some of these diseases abnormal tau inclusions are the most predominant neurodegenerative 
brain lesions (*) (modified from Gong et al. 2005).  
 
Disease 
Alzheimer’s disease (AD) 
Argyrophilic grain dementia* 
Bliut disease 
Corticobasal degeneration* 
Dementia pugilistica* 
Diffuse neurofibrillary tangles with calcification* 
Down’s syndrome (DS) 
Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17)* 
Gerstmann-Sträussler-Scheinker disease 
Guam parkinsonism dementia complex* 
Multiple system atrophy 
Myotonic dystrophy 
Neurodegeneration with brain iron accumulation type 1 (Hallevorden-Spatz disease) 
Niemann-Pick type C disease 
Pick’s disease* 
Post-encephalitic parkinsonism 
Prion diseases 
Progressive subcortical gliosis* 
Progressive supranuclear palsy* 
Subacute sclerosing panencephalitis 
Tangle only dementia* 
 
3 PCA AS A METHOD TO STUDY PROTEIN-PROTEIN INTERACTIONS 
Exploring prorein-protein interactions is crucial to understand biochemical pathways in a liv-
ing cell (Michnick 2001). Molecular pathways are networks consisting of protein complexes 
simultaneously assembling and disassembling hereby eliciting highly dynamic biochemical 
networks. Different strategies to investigate these interactions have been developed in order to 
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understand and define the function and organization of the genes, their products and complex 
biochemical networks (Michnick et al. 2007). Protein-fragment complementation assay 
(PCA) is one strategy to study the dynamics and kinetics of interacting proteins in the living 
cell. One of the key points when designing PCA fragmets is to try to prevent spontanious 
folding of the reporter protein fragments (Michnick et al. 2000). If spontanious folding cannot 
be prevented, the false-positive signal could confound the interpretation of the data received 
from protein-protein interactions.   
PCA is a method to investigate protein-protein interactions based on a reconstitution of en-
zyme activity of a reporter protein (Michnick 2001). In PCA, two complementary fragments 
of a reporter protein are both fused with two proteins of intrest. Due to an all-or-none nature 
of protein folding, when these fusion proteins interact, folding of a reporter protein to its na-
tive conformation restores the enzyme activity, which can be detected (figure 4). Therefore, in 
case the proteins of interest are not interacting, no signal can be detected. 
 
 
 
Figure 4. The principle of protein-fragment complementation assay (PCA). In the PCA, inter-
acting proteins of interest are fused to the two complementary fragments of a reporter protein 
(e.g. humanized Gaussia princeps luciferase, hGluc) (red and blue). Protein folding in a PCA 
is an all-or-none process. When the two proteins of interest interact in a cellular environment 
the unfolded reporter-protein fragments are brought into close proximity allowing them to 
fold into their active native conformation (1!2!3). The restoration of the enzyme activity 
enables the measurement of specific PCA reporter signal (e.g. luminescence). Depending on 
the endpoint application of proteins of interest (e.g. localization or quantification), the PCA-
reporter protein could be selected based on its features, for example reversibility or irreversi-
bility of the reporter dynamics (hGluc or green fluorescent protein, respectively) (modified 
from Michnick et al. 2007). 
 
PCAs based on photoproteins as reporters are highly useful for studying protein-protein in-
teractions (Tannous et al. 2005). Photoproteins, such as fluorescent and bioluminescent pro-
teins, have diverse properties, which can be used to investigate various phenomena in live-cell 
environment. Fluorescent proteins (e.g. green fluorescent protein (GFP) and YFP) are useful 
in trapping and visualizing more rarely occurring protein complexes due to irreversibility of 
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refolding of splitted fluorescent reporter protein (e.g. Hu et al. 2002). Furthermore, using fluo-
rescent proteins have been proved as a useful method to study the relocalization of complexes 
using small molecules to perturb the normal balance (Michnick et al. 2007). Irreversible pro-
tein folding is a general concern in PCAs by preventing the disassociation of the protein com-
plex, hereby preventing the studies of protein-protein kinetics or dynamics performed in the 
time frame of seconds or minutes. Unlike fluorescent-based PCAs, bioluminescence-based 
PCAs have been proved to be completely reversible (Remy & Michnick 2006). 
Bioluminescent proteins possess many beneficial properties concerning their use as recep-
tor proteins in PCAs (Remy & Michnick 2006). A class of bioluminescent proteins called 
luciferases catalyze an ATP-independent reaction where light is emitted (at a peak of 480 nm) 
due to substrate oxidation (Tannous et al. 2005). Luciferase enzyme, which is isolated from 
marine copepod Gaussia princeps, is composed of 185 amino acids (19.9 kDa) and uses coe-
lenterazine as a substrate. The humanized form of monomeric protein Gaussia luciferase 
(hGLuc) generates over 100-fold bioluminescense signal compared to other humanized forms 
of luciferases, such as Photinus pyralis (firefly, hFLuc) and Renilla reniformis (hRLuc), in 
cell lysates or in living cells. hFLuc differs from hRLuc and hGLuc by its different substrate 
(beetle D-luciferin) and its dependency on cofactors (ATP and Mg2+) for activity (Lembert & 
Idahl 1995). In addition, hFLuc has slow glow kinetics in contrast to rapid flash kinetics of 
hRLuc and hGLuc (Tannous et al. 2005). The substrate coelenterazine allows quantative 
analysis and real time monitoring of the conversion reaction through its ability to permeate 
cell membranes and thereby to diffuse into all cellular compartments (Remy & Michnick 
2006). Since being the smallest of all known coelenterazine-using luciferases, hGluc has great 
potential for diverse uses (Tannous et al. 2005).  
Regardless of the receptor protein used, PCA has many advantages studying protein-
protein interactions, whether concentrating on localization, quantification or investigating the 
dynamics of the proteins of intrest (Michnick et al. 2007). Particularly, perturbation of inter-
actions by genetic (gene overexpression or knockdown) or pharmacological means is an im-
portant and efficient strategy to study the alterations of specific biochemical pathways. 
Moreover, PCAs can be quite easily automated for high-throughput screening (HTS) to search 
for novel drug candidates and are also inexpensive. Split-GFP and split-luciferase PCAs both 
have specific investigation targets albeit they share at least some common features (table 3). 
The most crucial benefits with hGLuc-based PCA is the high sensitivity in real time detection 
of in vivo or in vitro studies and the ability to study the kinetics of assambly and disassambly 
of protein complexes in living cells (Remy & Michnick 2006). Although the method has 
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many advantages, it also has a few limitations. hGLuc PCA requires overexpression of re-
porter protein constructs which is always an aberration compared to normal condition of cell 
environment. Also, the addition of substrate is required to achieve an active reaction to induce 
bioluminecense, while fluorescent reporter proteins do not have this requirement. 
 
Table 3. Features of different methods to study protein-protein interactions. eBRET: Extended 
bioluminescence resonance energy transfer; FRET/FLIM: Förster (fluorescence) resonance 
energy transfer/fluorescence lifetime imaging microscopy; GFP: green fluorescent protein; 
hGLuc: humanized Gaussia princeps luciferase.  
 
Method Live cells  Localization Quantification Dynamics 
Immunoprecipitation - - + + - 
eBRET + + - + + + 
FRET/FLIM + + + + + + - 
Split fluorescent protein 
PCA (e.g. GFP) 
+ + + + + - 
Split bioluminescence pro-
tein PCA (e.g. hGLuc) 
+ + - + + + + 
 
4 AIMS OF THE STUDY 
Tau protein is one of the aggregating proteins in various neurodegenerative disorders such as 
Alzheimer’s disease and frontotemporal dementia. Dissociation of tau from microtubules and 
its intracellular aggregation is regulated by phosphorylation and dephosphorylation equilib-
rium. Studying the alterations of tau phosphorylation within live cell environment using small 
molecular compounds to induce or inhibit biochemicals pathways, could offer a novel method 
to study and further to understand the mechanism(s) of tau-driven neurodegeneration. Aims of 
the study were to 
- set up and validate PCA to investigate protein-protein interactions of tau in live cells 
- validate the conditions and perform high-throughput screening 
- confirm the possible hits from the screen using independent methods. 
5 MATERIALS AND METHODS 
5.1 Cloning 
All the cDNAs used in cloning were purchased from MGC IMAGE cDNA library (Open Bio-
systems). Inserts were amplified from cDNAs using PCR with specifically designed primers 
(Oligomer) and Phusion Hot Start DNA polymerase enzyme (Finnzymes) (table 4). Each 
PCR-program was determined separately considering the melting temperatures (Tm) of the 
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primers used. PCR-products were cut out from the 1% agarose gel after gel electrophoresis 
and were purified using QIAquick Gel Extraction kit (Qiagen). Purified insert DNAs were 
digested with various restriction enzymes (New England Biolabs, NEB) by single enzyme 
digestion and the DNA fragments were purified (MiniElute PCR Purification Kit from 
Qiagen) before second digestion. All restriction enzyme digestions were incubated 2 hours in 
37°C. After the second digestion inserts were purified (MiniElute PCR Purification Kit from 
Qiagen) and the concentrations were measured using NanoDrop 2000c spectrophotometer 
(Thermo Scientific). DNAs were eluted in Milli-Q water (mQH2O). 
 
Table 4. Primers (Oligomer) used in PCR-cloning of the constructs. Cdk5-construct was 
cloned by Prasanna Sakha. Primers HH-0004 and HH-0024 were used in colony PCR and in 
sequencing (HH-0004). 
   
Primer Sequence Tm Gene 
HH-0009B ATCGATGGGCGGACAGAAGTCGGA 61°C hCdk5 
HH-0009C GATATCACCGCCATGCAGAAATACGAGA 59°C hCdk5 
HH-0013C GAAGATCTACCGCCATGTCAGGGC 59°C hGSK3! 
HH-0013D TGAATTCGGTGGAGTTGGAAGCTGATG 59°C hGSK3! 
HH-0015F CGGGATCCACCGCCATGGCTGAGCCCCG 71°C hTau 
HH-0015G TGAATTCCAAACCCTGCTTGGCCAGGGAGG 66°C hTau 
HH-0017A GCGGCCGCACCGCCATGGCAGGAGCT 73°C hPPP2R2A 
HH-0017B ATCGATATTCACTTTGTCTTGAAATATATACAG 53°C hPPP2R2A 
HH-0018A GCGGCCGCACCGCCATGGATAAAAAT 65°C h14-3-3z 
HH-0018B ATCGATATTTTCCCCTCCTTCTCCTGCTTC 60°C h14-3-3z 
HH-0026D GAAGATCTACCGCCATGCATACAGG 57°C hDYRK1A 
HH-0026E TGAATTCCGAGCTAGCTACAGGACTC 58°C hDYRK1A 
HH-0034C CGGGATCCACCGCCATGGGCTGTG 66°C hFyn 
HH-0034D TGAATTCCAGGTTTTCACCAGGTTGGTACTGGGG 65°C hFyn 
HH-0048A CGGGATCCACCGCCATGGCGGAC 66°C hPin1 
HH-0048B TGAATTCCTCAGTGCGGAGGATGATGTGG 62°C hPin1 
HH-0004 TAGAAGGCACAGTCGAGG 50°C pcDNA3.1 
HH-0024 TAATACGACTCACTATAGGG 45°C pcDNA3.1 
 
 
Constructs phGLuc1-APP and phGLuc2-APP, which were kind gifts from Oksana Bere-
zovska (Massachusetts General Hospital, Boston, USA) with permission of Stephen W. 
Michnick (Université de Montréal, Montréal, Canada), were used as template plasmids for 
further modifications of phGluc-vectors. APP inserts were removed from the vectors by re-
striction enzyme (RE) digestions and the vectors were blunted using NEB Quick Blunting Kit 
(according to manufacturer’s protocol). After purification, self-ligation was performed for 
both blunted vectors using T4 DNA ligase (NEB) in room temperature (RT) for over night 
(o/n). Electroporation was used for transformation of plasmids to XL1 Blue electroporation 
competent cells (E. coli). In electroporation, 1 µl of self-ligated plasmid was pipetted to 
thawed XL1 Blue cells on ice, gently swirled and transfered into ice-cold cuvette. Electropo-
 31!
ration was proceeded using 2500 V for 0,5 milliseconds according to manufacturer’s protocol 
for high efficiency electrotransformation of E. Coli (MicroPulser, Bio Rad). Transformated 
cells were plated on LB-plates with suitable antibiotic after 1 h (37°C, shaker) incubation in 1 
ml of SOC media. Plates were incubated o/n in 37°C and checked for colonies. These resulted 
vectors containing more flexible multiple cloning sites (MCS), named phGluc(1C) and 
phGluc(2C), were used for cloning C-terminal hGluc fusion constructs (figure 5). 
 
 
 
Figure 5. Vectors phGluc(1C) and phGluc(2C). Plasmids were modified from original plas-
mids by removing the inserts, blunting and self-ligating the vector backbone. These vectors 
were used in most of the clonings of constructs that were further used in PCA. Vectors were 
digested at multiple cloning sites (MCS) with various restriction enzymes and ligated with 
identically digested inserts. 
 
Inserts and vectors were ligated using T4 DNA ligase (NEB) and 10X T4 ligation buffer 
(NEB) in 10 µl reactions which were incubated o/n in 12°C and transformed the following 
day to XL1 Blue cells (1 µl of ligation mix) using electroporation. Clones containing the in-
sert were screened using colony-PCR or by restriction enzyme digestions from miniprep 
DNA. Minipreps were produced by inoculating the colony into 3 ml of LB-medium (Luria- 
Bertani medium) with suitable antibiotic which after o/n incubation in 37°C on shaker were 
purified with QIAprep Spin Miniprep Kit (Qiagen). Verifications were done by using RE di-
gestions and gel electrophoresis. Colony-PCR screening was used when screening large num-
ber of colonies using Dynazyme II DNA polymerase (Finnzymes) and specifically designed 
primers (one primer having recognition site in the vector backbone, and the other primer in 
the insert). All positive clones were verified by sequencing (Institute of Biotechnology, Uni-
versity of Helsinki, Helsinki, Finland). 
 32!
5.2 Cell culture and transfections 
Mouse neuroblastoma (Neuro2A) cells were maintained at 37°C, 5% CO2 in fully supple-
mented Dulbecco’s Modified Eagle’s Medium (DMEM (Lonza) including 10% fetal bovine 
serum (FBS; Lonza), penicillin/streptomycin (Lonza) and L-Glutamine (Lonza)). Morphology 
and density of Neuro2A cells were monitored with microscope and the cells were passaged 
twice a week. Rat cortical neurons (RCN) were maintained in same conditions as Neuro2A, 
except that fully supplemented neurobasal medium (NB including 2% B27 (Invitrogen), 1% 
penicillin/streptomycin and 1% L-Glutamine) was used. RCNs were plated on Poly-L-lysine 
(Sigma) (1:10 diluted in mQH2O) coated 6-well plates in density of 400 000 cells per well in 
2 ml of full NB. 1/3 of the media was changed twice a week and due to an evaporation 100µl 
more media was added to the wells than pipetted out of the wells to maintain the total volume 
of 2 ml per well. 
 For transfections of Neuro2A cells plated on a Poly-L-lysine coated (Sigma) (1:10 diluted 
in mQH2O) white walled clear bottom plates (ViewPlate -96 TC, PerkinElmer), 8 000 or 10 
000 cells per well in 200 µl of full DMEM, were carried out using jetPEI* transfection rea-
gent (Polyplus Transfection) according to manufacturer’s protocol. 1:3 ratio of DNA: jetPEI 
was used (0,1 µg of DNA, 0,3 µl of jetPEI per well) diluted in suitable volume in 150 mM 
NaCl (parameters are for 96-well plate transfections). Cells were transfected 24 h post-plating 
and incubated in 37°C, 5% CO2. The validation of transfection efficiency and the selection of 
cell line used were done by Prasanna Sakha (Neuroscience Center, University of Helsinki, 
Helsinki, Finland). 
5.3 Immunofluorescence microscopy 
Neuro2A cells were plated on a Poly-L-lysine coated 6-well plate containing glass coverslips 
(3+9mm coverslips per well) at the density of 200 000 cells per well in 2 ml of fully supple-
mented DMEM. Cells were transiently transfected 24 h post-plating as described above using 
pEGFP-tubulin and phGluc(2C)-tau plasmids at ratio of 1:1. 24 h post-transfection the cells 
were fixed with 3% paraformaldehyde in PBS for 20 min and washed 3+2 min with PBS. 
Then, the coverslips were incubated in the blocking buffer (5% goat serum, 1% bovine serum 
albumin (BSA), 0,1% gelatin, 0,1% Triton X-100, 0,05% Tween-20 in PBS) for 1 h at RT. 
Next, the coverslips were incubated with the primary antibody Tau-5 (Invitrogen) diluted 
1:500 in primary antibody dilution buffer (1% BSA, 0,1% gelatin in PBS) at +4°C with gentle 
shaking over night. After washing the cells 3+3 min with PBS, Alexa Fluor-conjugated (568) 
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Goat anti-mouse secondary antibody (Molecular Probes/Invitrogen) was diluted 1:2 000, 
added to coverslips and incubated for 45 min, RT, shaker (protected from the light). To coun-
terstain the nuclei, the cells were again washed 3+3 min with PBS and then incubated with 
1:10 000 diluted Hoechst 33342 (Molecular Probes/Invitrogen) in PBS for 10 min following 
the washes of 2+2 min with PBS and once with mQH2O. Finally, the coverslips were 
mounted on microscope slides with ProLong Gold antifade reagent (Molecular 
Probes/Invitrogen), dried for 30 min and sealed on the microscope slides using nail polish. 
Microscope images were taken using epifluorescence microscope (Zeiss Axio Imager M1), 
which was equipped with a CCD camera (AxioCam HRm CCD). 
5.4 Protein-fragment complementation assay 
Protein-fragment complementation assays (PCA) were performed using Neuro2A cells. 8 000 
cells were plated on a 96-well plate in 200 µl of fully supplemented DMEM and transfected 
24 h post-plating as described. Prior to starting the treatments the wells were washed once 
with pre-warmed 1 + PBS (phosphate bufferd saline) after discarding the medium/transfection 
-mix from the wells, either by pipetting or flipping and tapping the plate. All the compounds 
used in the treatments were diluted to phenol-red free DMEM (PRF-DMEM, Invitrogen) con-
taining penicillin/streptomycin and without FCS and L-glutamine, which was also added to 
the cells to be left untreated (controls). The volume of the medium used in the incubations 
was 75 µl per well. Incubation times with treatments on varied from 1 h to 4 h and a minimum 
of 4 replicate wells of each treatment (or untreated) was used.  
The timing of treatments was planned so that the measurement of bioluminescence was 
performed 48 h post-transfection. The luciferase substrate used, native coelenterazine free 
base (nCol, NanoLight Technology), was dissolved in methanol (1 mg/ml) and further diluted 
into PRF-DMEM (80 µM). Immediately after well-by-well injection of 25 µl of nCol per 
well, resulting the final concentration of 20 µM nCol, the luminescence was measured (Vic-
tor3 1420 Multilabel counter with dispenser unit, PerkinElmer). Various measurement proto-
cols were used during the validation of PCA from which the protocol consisting of 1 second 
measurement repeated 5 times with 0,2 second interval in between was the mostly used. 
Avarage of the five 0,2 s readings was used as the reading per well.  
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5.5 High-throughput screening 
High-throughput screening (HTS) was carried out in cooperation with Dr. Päivi Tammela 
from Centre of Drug Research (CDR, University of Helsinki, Helsinki, Finland) using CDR’s 
libraries of pharmaceutical compounds (PC) (appendix 1) and natural compounds (NC) (ap-
pendix 2). PCs and NCs were pre-diluted in dimethyl sulfoxide (DMSO) on 96-well master 
plates (10 mM and 20 mM, respectively) by Dr. Päivi Tammela. The interaction pair selected 
and used in the HTS was tau-Pin1. 
 The sample plates were prepared manually from master plates by diluting the pre-diluted 
stock solutions to desired concentrations in PRF-DMEM. At the primary screening round the 
concentration used for compounds was 50 µM, 4 replicate wells each. Hence, one assay plate 
contained 20 different compounds to be tested and untransfected-, 5 µM Juglone- and 25 mM 
KCl controls, 4 replicate wells each. The first screening round included the whole PC/NC 
library containing altogether 355 compounds (240 and 115, respectively). On the secondary 
screening round, 5 different concentrations  (50 µM, 25 µM, 12,5 µM, 6,25 µM and 3,125 
µM, 4 replicate wells each) were used for selected compounds (15 PCs, fresly dissolved) to 
verify results from the first round. Based on the observations from the second round, the third 
screening round was performed using logaritmic concentrations (50 µM, 5 µM, 0,5 µM, 0,05 
µM and 0,005 µM) for further selected compounds (7 PCs and 5 NCs).  
The plating of Neuro2A cells (10 000 per well) and transfections for HTS were performed 
as described. 46 h post-transfection the assay plates were washed once with warm (37°C) 1 + 
PBS semi-automatically by tilting the plate over and tapping the plate gently against paper 
towel to empty the wells (DMEM and transfection mix), added the 1 + PBS using robot 
(Beckman Coulter Biomek FX Dual-pod workstation) and discarded the PBS as described. 
Robotics was also used for addition of compounds from pre-warmed sample plates to assay 
plates. Treatment time was 2 h. The measurements were performed using Varioskan Flash 
(Thermo Scientific) using measurement protocol; 0,2 second measurement repeated 5 times 
per well without pause in between. The luminescence was measured well-by-well immediatly 
after the injection of the substrate.  
5.6 Western blotting 
Proteins were extracted from 21 days in vitro (DIV) rat cortical neurons (RCNs) after 2 h 
treatments (also 6 h and 24 h treatments were tested) using ice-cold full extraction (GTIP) 
buffer (for 10 ml: 1 ml 10 + GTIP buffer (100 mM Tris pH 7,6, 20 mM EDTA and 1,5 M 
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NaCl), 25 µl NP40 (Igepal CA-630, Sigma), 1% TritonX-100 (Sigma), 1 pill of complete 
Mini-EDTA free (protease inhibitor cocktail, Roche), 1 pill of PhosStop (phosphatase inhibi-
tor cocktail, Roche), 100 µl 0,1M NaF and 8 ml mQH2O) (table 5). The volume of full NB of 
each well was measured and adjusted to 2 ml the previous day before the treatments. Protein 
concentrations of the cell lysates were determined using BCA Protein Assay (Pierce/Thermo 
scientific) and the samples were prepared in the total volume of 40 µl including 4 + gel-
loading buffer (NuPAGE LDS buffer, Invitrogen) containing !-mercaptoethanol. Samples and 
standards (Precision Plus Protein Kaleidoscope, Bio-Rad) were loaded into NuPage 4-12% 
Bis-Tris Gels (Invitrogen) and the gels were run using XCell SureLock Mini-Cell (Invitrogen) 
containing 1 + MES SDS Running buffer (170 V, 60 min).  
 
Table 5. Controls and pharmaceutical compounds (PC) used in RCN treatments. The final 
concentration for all the PCs used was 50 µM which were added directly into the media (fully 
supplemented neurobasal) and incubated in 37°C, 5 % CO2 for 2 h prior to protein extraction. 
PCs were obtained from Centre of Drug Research (CDR, University of Helsinki, Finland) and 
diluted into DMSO (10 mM stocks). 
 
Treatment compound Description 
DMSO (0.5 %) Control (untreated) 
5-Hydroxy-1,4-naphthoquinone (Juglone) (5 µM) Control (Pin1 inhibitor)  
Calyculin A (10 nM) Control (PP2A inhibitor) 
Allobarbital Sedative 
Butethal Sedative 
Clopenthixol dihydrochloride Antipschotic 
Selegiline hydrochloride Monoamine oxidase inhibitor 
Desalkylflurazepam Hypnotic 
Diazepam Anxiolytic, muscle relaxant 
Pentobarbital Sedative 
 
 
Blotting (semi-dry) of the proteins was performed using Bio-Rad Trans-Blot SD Semi-Dry 
Transfer Cell (20 V, 35 min). Pre-blotting soaked the extra thick blotting papers, pre-ran gels 
and PVFD-membranes (pre-soaked 1 min in methanol) for 10 min in 1+ transfer buffer (1 + 
Semi-Dry Western blotting buffer; for 1 L; 100 ml 10 + Semi-Dry Western blotting buffer 
stock (480 mM Tris, 390 mM glycine, 13 mM SDS), 200 ml MeOH, 700 ml reverse osmosis 
H2O). After blocking (5% milk powder in 1+ TBST) and washing (1 + TBST) membranes 
were incubated with anti-bodies AT8 (Innogenetics, Invitogen) and TG3, which was a kind 
gift from Jin-Jing Pei (Karolinska Institutet, Stockholm, Sweden), PHF13 (Cell Signaling) 
and GAPDH (Millipore). For chemiluminescent detection, Pierce ECL Western Blotting Sub-
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strate (Thermo scientific) was used and membranes were exposed on Kodak Biomax light 
films which were developed using a Kodak X-OMAT 1000 processor. 
5.7 Phosphatase activity assay 
The phosphatase activity assay was performed according to manufacturer’s protocol, provided 
in the Serine/Threonine Phosphatase Assay System (V2460, Promega). First, cell lysates were 
prepared from 21 DIV RCNs (2 + 6-well plates, 400 000 cells/well). After the cells were 
washed once with ice-cold phosphatase storage buffer (PhSB, 50 mM Tris-HCl pH 7,4, 0,25 
M sucrose, 0,1 M EDTA) cells were lysed in 75µl of ice-cold full PhSB (PhSB including 
0,1% !-mercaptoethanol, protease inhibitor cocktail pill (complete Mini-EDTA free, Roche)) 
and collected using cell scrapers (modified from Planel et al. 2001). Cells from 6-wells were 
pooled into one sample tube, incubated on ice for 20 min and were pulled 10 times through a 
needle (1 ml syringe with 22 G + 1", needle). Pooled samples were centrifuged for 1 h at 100 
000 + g at +4°C (Beckman TL-100 ultracentrifuge, TLA-55 rotor) and supernatants were then 
transferred into fresh tubes on ice. After stabilizing the spin columns, according to manufac-
turer’s protocol, the cell lysates were pipetted into the spin columns, centrifuged for 5 min at 
600 + g at +4°C to remove endogenous free phosphate and pooled the lysates resulting one 
lysate sample. Protein concentration of the cell lysate was determined. 
 The PP2A assay was performed according to manufacturers protocol (Phosphatase Assay 
protocol, Promega) using the supplied " -area flat-bottom 96-well plate in the final volume of 
50 µl/reaction. The 5 + PPase buffer used was 5 + PP2A buffer (250 mM imidazole, 1 mM 
EGTA, 0,1% !-mercaptoethanol, 0,5 mg/ml bovine serum albumin (BSA)). All the reactions 
and proper controls were done in duplicates/triplicates and were incubated at 37°C for 30 min 
before stopping the reactions by adding the Molybdate dye/additive mixture. After 15 min of 
incubation in room temperature the PP2A activity was determined by measuring the absor-
bance (620 nm) of released phosphate-molybdate-malachite green complex. 
5.8 Statistical analyses 
Statistical analyses were performed using either the analysis of variance (three or more 
groups, which were followed by Bonferroni’s post-tests) or using the Student’s t test (two 
groups) in GraphPad Prism software. Significance was placed at p < 0.05. 
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6 RESULTS 
6.1 Live-cell detection of tau interactions in PCA and HTS 
6.1.1 Protein-fragment complementation assay 
Tau protein is known to interact with numerous molecules in the cell environment under nor-
mal physiological and also under pathophysiologigal conditions. To study the interactions of 
tau in a living cell assay with its known interactors, multiple constructs were generated (figure 
6). The luminescence signal of various tau interaction pairs was measured to confirm that the 
signal is detectable and feasible compared to control. 
 
 
 
Figure 6. Schematic presentation of hGluc fragment-tagged reporter constructs. Schematic 
presentation of cloned constructs that were used to study protein-protein interactions of tau in 
live cells by using hGluc-based PCA strategy. In all constructs the hGluc tag was cloned in 
the C-terminus of the protein. Human tau isoform 0N4R was used throughout the study. 
 
To test whether the hGluc-tag affects its cellular localization, phGluc(2C)-tau construct was 
overexpressed in cells with GFP-tubulin. Immunofluorescence microscopy experiments 
showed the localization of tau into neurites and cysoskeletal structures, suggesting that hGluc-
tag does not interfere with the normal function and localization of tau in Neuro2A cells (fig-
ure 7A). Additionally to verification of hGluc-plasmids by DNA sequencing, the identity and 
expression of these fusion constructs were also verified in cells by Western blotting (figure 
7B). Moreover, the responsiveness of PPIs to various inhibitors and other stimuli is crucial to 
confirm normal functionality. The major focus of the tau interacting molecules was protein 
kinases and protein phosphatases (PPs), which are known to contribute to the phosphorylation 
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equilibrium of tau, and molecules which participate in the regulation of phosphorylation state 
of tau and binding of tau into cellular structures (Pin1 and !-tubulin, respectively). 
 
 
 
Figure 7. Subcellular localization of hGluc2-tau and the expression of the hGluc tagged fusion 
reporter proteins. Neuro2A cells were transiently transfected with hGluc2-tau and EGFP-
tubulin to assess the normal localization of the tau fusion protein (A). The subcellular local-
ization of hGluc2-tau (red) and EGFP-tubulin (green) were analyzed by immunofluerescence 
microscopy. Tau was detected with immunostaining using Tau-5 antibody. Localization of the 
fusion proteins to neurites and cytoskeletal structures in coexpressing cells indicates that 
hGluc fusion tag of tau does not interfere with its normal cellular functions and localization. 
The nuclei were counter-stained with Hoechst 33342. The expression of the hGluc tagged 
fusion reporter proteins was analyzed in Neuro2A cells by Western blot (B). The blots were 
stained with antibodies to tau (Tau-5) and Pin1. GAPDH antibody was used as a loading con-
trol. 
6.1.2 PCA set up and optimization for High-throughput screening 
The selection of the interaction pair for tau was the first step in the set up for PCA-based 
screening experiment. Based on the relatively high signal level and repetition of responsive-
ness to inhibition using juglone and to induction using KCl, Pin1 was chosen (figure 8A & B). 
Juglone, a known selective natural compound, is a cell-permeable and irreversible inhibitor of 
parvulin-like PPIases, such as E. coli parvulin and human Pin1 with IC50 of approximately 
1.5 µM (Hennig et al. 1998). Furthermore, by increasing the media KCl concentration leading 
to cell depolarization has been reported to increase tau phosphorylation (Pierrot et al. 2006), 
which is also consistent with our PCA data. The critical facilitative function of Pin1 in 
dephosphorylation of specific disease-associated proline-directed serine and threonine sites on 
tau offers a feasible approach to study tau PPIs in this live-cell system. 
A B 
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Figure 8. Validation of hGluc-based PCA for detection of Pin1-tau interaction. Pin1-tau inter-
action was pharmacologically validated to test the bidirectional response to stimuli. 48 h post-
transfection, transiently transfected Neuro2A cells were treated with 1 µM or 5 µM Juglone 
(Pin1 inhibitor) (A) or 25 mM KCl (B). Luminescence signal was measured by flash lumi-
nometry in live cells followed by normalization of the values to corresponding data from !-
galactosidase assay that was used as an internal vector control per well. The average values 
are displayed as percent change as compared to vehicle-treated control cells (means ± S.E.M.; 
4 replicate wells per experiment, 4 independent experiments). ** indicate significant differ-
ence with p < 0.01. 
 
To determine the optimal conditions for screening of small molecular libraries, different 
parameters were thoroughly studied. First, the maximum amount of vehicle (DMSO) that 
does not affect the basal signal and is not toxic to cells in our experimental set up time range 
was evaluated (figure 9A). The percentage of 0.5 % was determined for maximal concentra-
tion to be used in the screening. This decision was partly based on the concentration of the 
pre-diluted PC and NC master plates (10 mM and 20 mM, respectively). Second, the amount 
of cells per well in 96-well plate, ranging from 4 000-10 000, was tested using different trans-
fection protocols with variable amount of DNA and transfection reagent (figure 9B). Using 
10 000 cells per well resulted in the highest transfection efficiency and the lowest variation. 
Third, various measurement program protocols were tested using different measurement times 
and changing the pause time between the five measuments taken per well (figure 9C). Due to 
its low variability, although the signal level was slightly decreased, the protocol with 1 second 
measurement and a 0.2 second delay between the readings was chosen.  
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Figure 9. Validation of optimal conditions of hGluc-based PCA for high-throughput screen-
ing. Various parameters were validated for optimal screening conditions of small molecular 
libraries. The maximum amount of vehicle (DMSO) that does not significantly affect the ba-
sal signal level and viability of the cells was tested (A). The number of cells per well ranging 
from 4000 to 10000 cells was tested (B). Also, depending on the cell number, different 
amounts of DNA and transfection reagent were used. For optimal measurement time frame 
window, five different measurement protocol programs were tested. Measurement times (m) 
and pauses between the measurements (p) varied from 0,2 seconds to 2 seconds and from 0,0 
seconds to 1,0 seconds, respectively. Luminescence signal was measured by flash luminome-
try in live cells. RLU; relative luminescence units. 
 
Bidirectional responsiveness of tau-Pin1 reporter system was further functionally studied. 
Co-overexpression of tau-Pin1 reporters with pcDNA3-GSK-3! resulted in a nearly two-fold 
increase in PCA signal compared to mock-transfected cells (empty pcDNA6-V5/His-C ex-
pression vector) (figure 10A). This effect was almost totally abolished in GSK-3! overex-
pressing cells by SB 216763, a specific GSK-3! inhibitor. Moreover, Neuro2A cells were 
transfected with either phGluc(2C)-tau alone or with pcDNA3-GSK-3! and treated with SB 
216763, Calyculin A or vehicle. After the protein extraction, the level of tau phosphorylation 
at specific epitopes was detected on Western blots. The data from the immunoblots showed 
that the overexpression of GSK-3! increases the phosphorylation of tau at least in epitopes 
AT8 and PHF13 (figure 10B). Altogether, these functional validation data suggest that tau-
Pin1 interaction pair responds to both biochemical and genetical stimuli in a predictable way 
providing evidence of feasibility to further investigate this interaction.   
 
 
Figure 10. Validation of hGluc-based PCA for detection of Pin1-tau interaction by using 
GSK-3! overexpression. Pin1-tau interaction was genetically validated by co-overexpression 
of GSK-3! to test its effect on PCA signal and tau phosphorylation status. Neuro2A cells 
were cotransfected with reporter constructs hGluc1-Pin1 and hGluc2-tau together with either 
empty mock plasmid (control) or with pcDNA3-GSK-3! (A). The vehicle treated cells co-
transfected with pcDNA3-GSK-3! generated nearly two fold signal compared to control cells 
A B 
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and to pcDNA3-GSK-3! cotransfected cells treated with GSK-3! inhibitor SB 216763. Lu-
minescence signal was measured by flash luminometry in live cells followed by normalization 
of the values to corresponding data from !-galactosidase assay that was used as an internal 
vector control per well. The average values are displayed as percent change as compared to 
vehicle-treated control cells (means ± S.E.M.; 4 replicate wells per experiment, 4 independent 
experiments). GSK-3! overexpressing cells were analyzed by Western blot (B). Neuro2A 
cells were transiently transfected with empty mock plasmid or hGluc2-tau with or without 
pcDNA3-GSK-3! as indicated. Before harvest, the cells were treated for 2 h with vehicle, 100 
nM SB 216763 or 10 nM Calyculin A. The blots were stained with phospho-specific tau anti-
bodies PHF13 and AT8 and Tau-5 to detect total tau levels. To verify GSK-3! overexpres-
sion, the blots were stained with GSK-3! and phospho-GSK-3! (Ser9) antibodies. GAPDH 
antibody was used as a loading control. * and ** indicate significant differences with p < 0.05 
and p < 0.01 respectively. SB; SB 216763, Caly; Calyculin A. 
6.1.3 High-throughput screening 
Based on the validation data, the screening of small molecular compounds using tau-Pin1 
interaction PCA was performed. First, the treshfold percentage to identify possible hits was 
determined for increased PCA signal (200%) and decreased PCA signal (75%) compared to 
DMSO vehicle control. The interaction was screened with focused libraries of known phar-
maceutical compounds (240) and natural compounds (115) (appendices 1 and 2, respectively). 
There were two drug classes that most commonly repeated among the hit compounds. Sul-
fonamide antibacterials and sedative-hypnotics comprised more than 40% of the hits in tau-
Pin1 screen (table 6). Noticeable differences were detected in the PCA signals between the 
wells treated with these small molecular modulators of the libraries, which implicates that the 
assay is responding to stimuli, and, thereby suggests that the PCA approach is suitable for 
screening small molecular modulators of tau PPIs (figure 11).  
 
 
 
Figure 11. An example of raw data obtained from five combined 96-well plates from primary 
screening of small molecular modulators of Pin1-tau interaction. Each bar (blue) represents 
the luminescence values detected from Pin1-tau PCA from four replicate wells per compound. 
The average values are displayed as percent change as compared to vehicle-treated control 
(dark green) cells. 5 µM juglone (orange) and 25 mM KCl (light green) were used as controls 
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on each 96-well plate. Hit area (above 200% or below 75%) is marked in semi-transparent red 
color. 
 
The primary screen yielded 26 preliminary hits from the pharmaceutical compound library 
from which 21 increased and 5 decreased tau-Pin1 PCA signal (table 6). 2 out of 5 initial hits 
that decreased the PCA signal were determined as false positive hits (appendix 3, false posi-
tive hits not included). This was due to incompatibility of these compounds in luminescence-
based PCA screen resulting in almost total loss of signal of tau-Pin1. Furthermore, these in-
compatible compounds were verified as false positive hits according to identical results ob-
tained from the screen performed simultaneously on APP metabolism by Prasanna Sakha 
(Neuroscience Center, University of Helsinki, Helsinki, Finland) (unpublished data). The 
screen from the natural compounds also yielded a few hits, from which all decreased the sig-
nal. Although among these hits there were some very interesting compounds included, the rest 
of the study was decided to proceed through by only investigating the hits from the pharma-
ceutical compounds and leave the natural compounds for further studies.  
 
Table 6. Summary of hits of pharmaceutical compounds from tau-Pin1 screening. 
 
Compounds screened 240 
Total number of hits 26 
Total number of excluded hits based on assay incompatibility  2 
Hit rate 10.0% 
Total number of compounds increasing the interaction 21 
Total number of compounds decreasing the interaction 3 
Most commonly repeated drug classes:   
   - Sedatives (barbiturates or benzodiazepines):  5 
   - Sulfonamide antibacterials: 3 
 
Next, we confirmed the hits in dose-response assays. 14 compounds were chosen for sec-
ondary screening (appendix 4). These 14 compounds were selected based on the signal levels 
from the first screen and their compound characteristics, which included predetermined thera-
peutic functions and ruling out compounds that would be incompatible for CNS use (e.g. topi-
cally applied antiseptics). Moreover, in the dose-response experiments the effect of sulfona-
mide antibacterials could not be consistently confirmed. In contrast, the secondary screening 
verified the increase of the tau-Pin1 interaction observed in the primary screen by sedative-
hypnotics. The increase of the sedative treated tau-Pin1 signal compared to vehicle treated 
cells varied between 1,4-2,0-fold depending on the compound used. However, the increase in 
tau-Pin1 PCA signal was slightly lower in the secondary testing compared to primary screen. 
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The effect of two sedative-hypnotics and folic acid, which was one of the few compounds 
identified to decrease tau-Pin1 interaction, were further validated in PCA using internal vector 
control (figure 12). Butethal, a barbiturate, and desalkylflurazepam, a benzodiazepine, both 
dose-dependently increased tau-Pin1 interaction, whereas consistent dose-dependent decrease 
was observed in cells exposed to folic acid. 
 
 
 
 
Figure 12. Validation of hit compounds with hGluc-based protein-fragment complementation 
assay (PCA) for detection of tau-Pin1 interaction. Transiently transfected (constructs hGluc1-
Pin1 and hGluc2-tau) Neuro2A cells were treated for 2 h with increasing consentrations of 
butethal (A, left panel) or desalkylflurazepam (A, right panel) or folic acid (B) 48 h post-
transfection. Luminescence signal was measured by flash luminometry in live cells followed 
by normalization of the values to corresponding data from !-galactosidase assay that was used 
as an internal vector control per well. The average values are displayed as percentages of 
change as compared with vehicle-treated control cells (means ± S.E.M.; n = 3). *, **, and *** 
indicate significant differences with p < 0.05, p < 0.01, and p < 0.001, respectively. 
6.2 Pharmacological modulation of neurons and mechanistic studies 
6.2.1 Treatments of mature RCNs and Western blot analyzes 
The sedative-elicited increase in tau-Pin1 PCA signal that was detected in the screening was 
subsequently examined in mature (21 DIV) rat cortical neurons (RCNs). To test whether the 
increased signal was due to increased phosphorylation of tau, RCNs were treated with 7 dif-
ferent compounds for 2 h with proper controls included (table 5). From the compounds tested 
on mature RCNs, butethal and desalkylflurazepam showed significant increases in tau phos-
phorylation at AT8 phosphoepitope (Ser199/Ser202/Thr205) analyzed on Western blot (figure 
13). Unexpectedly, large differences were seen in tau phosphorylation status between the dif-
ferent compounds within the same compound classes (barbiturates and benzodiazepines). 
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Hence, according these data, barbiturate butethal and benzodiazepine desalkylflurazepam 
were chosen for further studies.  
 
 
 
Figure 13. Effect of hit compounds on mature rat cortical neurons. 21 DIV rat cortical neu-
rons (RCNs) were treated for 2 h with various hit compounds identified from the screen of 
small molecular modulators at 50 µM concentration. Different compounds (4 out of 7 tested 
depicted here) showed large variation in the phosphorylation status of tau at AT8 phosphoepi-
tope even within the same compound classes (barbiturates; allobarbital and butethal, benzodi-
azepines; desalkylflurazepam and diazepam) when analyzed by Western blot. Juglone and 
Calyculin A was used as controls. GAPDH antibody was used as a loading control. 
 
Next, dose-dependent experiments were performed using these two sedatives with lower 
concentrations (0,1 µM, 1 µM and 10 µM) compared to previous treatments (50 µM). Addi-
tionally, the treatment time was also extended to 6 h with the exception of controls, which 
remained in 2 h because of their potential long-term toxicity to neurons. Besides AT8 phos-
phoepitope, other AD-related tau epitopes were examined on Western blot. Treatments with 
increasing doses of butethal and desalkylflurazepam, which both are positive modulators of $-
aminobutyric acid type A (GABAA) receptors, resulted in increased tau phosphorylation at 
AT8 epitope, whereas no alterations in phosphorylation status were detected when probed 
with TG3 (Thr231/Ser235) or PHF13 (Ser396) phosphoepitopes (figure 14A & B).  
Furthermore, to study the stability of the effect observed with these compounds, a washout 
experiment was performed. RCNs were treated with 50 µM butethal or desalkylflurazepam 
for either 24 h or 48 h. 24 h treatments were followed by a washout period of 24 h (i.e. after 
the incubation of 24 h with compound, the culture media was replaced to fresh full NB with-
out the compounds for a period of 24 h before the protein extraction). The phosphorylation at 
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AT8 epitope remained at elevated level after the 24 h washout period compared to vehicle 
treated neurons (figure 14C). Taken together, butethal and desalkylflurazepam both increase 
tau phosphorylation at the AT8 epitope and the effect is clearly detectable even after the 
washout period of 24 h.  
 
 
 
 
 
 
Figure 14. Effect of GABAA receptor modulators on mature rat cortical neurons. Mature pri-
mary rat cortical neurons (21DIV) were treated with three different concentrations of butethal 
and desalkylflurazepam for 6 h (A). Western blot analyzes were performed to cell extracts 
using phosphospecific tau antibodies (AT8, TG3 and PHF13). Treatments with both butethal 
and desalkylflurazepam increased the phosphorylation of tau at AT8 epitope compared to 
vehicle treated controls. (B) Optical density quantification of the AT8 epitope phosphoryla-
tion of tau from Western blot (figure 14A). (C) 21 DIV primary rat cortical neurons were 
treated 50 µM butethal and desalkylflurazepam for 48 h or treated for 24 h followed by a 
washout period of 24 h where drugs were removed from the cells and replaced with fresh me-
dia without the GABAA active drugs. As compared to vehicle treated controls, increased 
phosphorylation of tau at AT8 epitope induced by butethal and desalkylflurazepam remained 
at an elevated level after the 24 h washout period. GAPDH antibody was used as a loading 
control. BUT; butethal, DAF; desalkylflurazepam, Veh; vehicle. 
6.2.2 Role of PP2A in sedative induced increase in tau phosphorylation 
PP2A is the major protein phosphatase suggested to dephosphorylate tau and its interaction 
with tau is dependent on Pin1-catalyzed cis/trans proline isomerization that preceeds the 
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phosphorylated serine/threonine residues. The PP2A activity was studied from 21 DIV rat 
cortical neurons to assess if the sedatives have a direct effect on PP2A activity in vitro. In this 
cell-free assay, either butethal or desalkylflurazepam does not seem to directly decrease PP2A 
activity while calyculin A, a PP2A inhibitor, has a significant effect reducing the enzyme ac-
tivity (figure 15A).  
   
 
 
Figure 15. Enzymatic activity of protein phosphatase 2A (PP2A) in a cell-free assay and 
PP2A-tau interaction in Neuro2A cells. To test the direct effects of GABAA receptor activa-
tors on PP2A activity, the samples were treated with butethal and desalkylflurazepam in a 
cell-free assay (A). The enzymatic activity of PP2A was not altered when treated with 
GABAA active drugs, whereas Calyculin A treatment, a potent PP2A inhibitor, resulted in 
significant reduction in the enzymatic activity. However, decrease of nearly 50 % in PP2A-
tau interaction was detected in intact transiently transfected cells when treated with GABAA 
receptor modulators (C). Juglone (Pin1 inhibitor) was utilized in the pharmacological valida-
tion of the PP2A-tau interaction (B). The average values are displayed as percentages of 
change as compared with vehicle-treated control cells (means ± S.E.M.; n = 3). * and ** indi-
cate significant differences with p < 0.05 and p < 0.01, respectively.  
 
The interaction of tau and PP2A was also studied using PCA platform. Since PP2A-tau in-
teraction depends on Pin1 activity, PP2A-tau PCA was validated with Juglone (1 µM and 10 
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µM) to test its functionality and the effect of the sedatives was further studied (figure 15B). 
Treatment of Neuro2A cells overexpressing tau and PP2A hGluc plasmids with these seda-
tives showed a reduction of nearly 50% in the PCA signal (figure 15C). Although butethal or 
desalkylflurazepam do not affect the enzyme activity of PP2A in cell-free in vitro assay, the 
interaction of these proteins in intact cells is clearly reduced. 
 
The results presented in this MSc. thesis have been published in The Journal of Biological 
Chemistry (Vol. 287, No. 9, pp. 6743–6752, February 24, 2012) by Niko-Petteri Nykänen, 
Kai Kysenius, Prasanna Sakha, Päivi Tammela and Henri J. Huttunen. All of the experimental 
procedures and the results presented in here were performed and produced by the author of 
this thesis unless otherwise mentioned. 
7 DISCUSSION 
7.1 Experimental procedures and results 
In the cellular environment, there is a constant flux of a myriad of molecular interactions, 
which are highly sensitive to alterations in the ambient conditions. When using live cell ap-
proaches, it is highly important to try to minimize the fluctuation in the data by using exactly 
the same conditions throughout a single experiment and in the subsequent replicate experi-
ments. Factors that may create changes in the normal physiological state of the cell, such as 
transfection to induce overexpression of certain proteins, treatment with modulators of spe-
cific cellular functions and exposure times should be under careful consideration. Thus, thor-
ough functional validation of each experiment, and in this case each PPI pair separately, is 
instrumental when working with live cell assays. Furthermore, the selection of the cell line or 
primary cells used is essential to obtain information from the target of interest and also to as-
sess which cells are the most feasible in a certain phase of an experiment. Moreover, the char-
acteristics of the cells used, such as endogenous expression of specific proteins and suitability 
of the cells  (e.g. transfection efficiency, division rate) to experimental workflow are crucial 
properties to produce reliable and repeatable data. For example, mouse neuroblastoma 2A 
cells, which were mostly employed in this study, are neural like tumor-derived cells with a 
rapid division cycle and high transfection efficiency properties, which provides feasible basis 
to study protein-protein interactions. Nevertheless, the suitable properties of Neuro-2A to in-
vestigate PPIs, the networking of the cells and structural and functional properties still highly 
differs from primary neurons, which emphasizes the further utilization of neurons as a proper 
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in vitro study platform to investigate neuronal phenomena. However, primary neurons pose 
other technical challenges, such as difficulty to transfect with high efficiency.   
 Reliable and repeatable positive and negative controls are fundamental for interpretation of 
the data regardless of the experiment design. To rule out any false positive signal in PCA ex-
periments, only one of the split luciferase fragments including the insert of protein of interest 
was transfected. These cells did not emit any detectable luminescence compared to untrans-
fected cells and therefore were used as a background control (data not shown). To further rule 
out the additional false positive results, the spontaneous folding of the complementary lu-
ciferase enzyme fragments without any fusion proteins were studied providing similar results 
as the transfection of only other hGluc fragment. Moreover, the tagging of the protein of in-
terest with e.g. His-tag, TA-tag or hGluc-tag may effect on the physiological function and the 
subcellular localization of the protein. In this study it was shown that hGluc-tagged tau colo-
calizes with GFP-tubulin to cytoskeletal structures and neurites suggesting that the hGluc-tag 
does not interfere the normal function and cellular localization of tau. Moreover, hGluc-
tagged tau was normally phosphorylated in multiple epitopes in response to GSK-3! overex-
pression. 
Because of the critical role of Pin1 in tau dephosphorylation in neurons (Lu et al. 1999) 
and the encouraging results obtained from the primary PCA experiments, Pin1-tau interaction 
was chosen as a dynamic live cell protein-protein interaction reporter to focus on further stud-
ies. The data from the functional validation experiments showed that the bidirectional respon-
siveness of Pin1-tau PCA to genetic stimulation using GSK-3! overexpression, and also to 
pharmacological modulation using Juglone for inhibition of Pin1. Western blot studies of 
Neuro-2A cells, which were transfected with either tau-Gluc fusion protein alone or cotrans-
fected with GSK-3! showed that GSK-3! overexpression promotes phosphorylation of tau 
fusion protein at probed AT8 and PHF13 epitopes. Hence, based on these data, it was con-
cluded that hGluc-based protein-fragment complementation assay is suitable for studying tau 
PPIs in live cells.  
After the functional validation of the PCA assay, a high-throughput screening (HTS) was 
performed to search for molecules to increase or decrease tau-Pin1 interaction. In this case, a 
proof-of-concept screen is a more adequate term to describe the screening than HTS because 
of its strong focus to known pharmaceuticals and natural compounds and, also, the rather lim-
ited number of molecules screened compared to general description of HTS, in which the li-
braries may contain small molecular compounds from 100 000 to even up to one million. 
Nevertheless, the proof-of-concept screening showed that the PCA based assay is capable of 
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detecting novel modulators of tau PPIs. For example, folic acid, which was one of the few 
compounds identified from the screen to decrease the Pin1-tau interaction, has been previ-
ously reported to affect the methylation and maturation of PP2A complex thereby resulting in 
altered tau phosphorylation (Sontag et al. 2008). This is consistent with the data presented 
here showing that folic acid is reducing the tau-Pin1 interaction signal levels and, therefore, 
likely correspond with the phosphorylation state of tau. Interestingly, it has been reported that 
higher folate intake is associated with reduced incidence of Alzheimer’s disease in the elderly 
(Luchsinger et al. 2007). 
 The results of the proof-of-concept screen identified two compound classes that increased 
the tau-Pin1 interaction. These somewhat unexpected hit compounds belonging to the barbitu-
rates and benzodiazepines are both known modulators of $-aminobutyric acid type A 
(GABAA) receptors (e.g. Jacob et al. 2008). Neuro-2A cells, which were the cells utilized in 
the proof-of-concept screen are known to express functional GABAA receptors (Baraldi et al. 
1979), which suggests that the observed increase in Pin1-tau interaction may result from en-
hanced GABA signaling. Previously it has been shown that tau is functionally linked to traf-
ficking of NMDA receptors (Ittner et al. 2010) and there are also implications of increased tau 
phosphorylation in response to dopamine receptor D1 activation (Lebel et al. 2009; Lebel & 
Cyr 2011). To date, with the exception of those previously mentioned examples, tau has not 
been directly functionally linked in other neurotransmitter receptor systems. On the other 
hand, interesting findings have been observed in the modulation of tau phosphorylation in the 
cortex and hippocampus induced by various anesthetics that also affect GABAA transmission 
in the brain (Planel et al. 2007). Moreover, it has been suggested that PHF-like hyperphos-
phorylation of tau is a reversible event in hibernating mammals (Arendt et al. 2003). In addi-
tion to different neurotransmitter systems and central nervous system (CNS) active drugs re-
sponsible for altered tau phosphorylation, this may implicate a more general association be-
tween the level of neuronal activity and tau phosphorylation. 
 The most of the fast inhibitory neurotransmission in the mammalian brain is mediated by 
signalling through GABAA receptors (GABAARs) (e.g. Jacob et al. 2008; Luscher et al. 2011). 
The GABAARs belong to the superfamily of ligand-gated ion-channels and are abundantly 
expressed in neurons throughout the CNS and, also, are clinically significant drug targets for 
multiple CNS-active agents such as anti-convulsants, sedative-hypnotics and anxiolytics. 
GABAARs comprise a family of ligand-gated chloride channels wih a vast number of various 
subunit composition. 19 different GABAAR subunits have been identified to date, which are 
divided into eight subunit classes (#1-6, !1-3, $1-3, -, %, ., /, 01-3) based on their sequence 
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homology (e.g. Luscher et al. 2011). In addition, the alternative splicing of receptor mRNAs 
further increases the structural diversity of GABAARs. However, the most common receptor 
subunit composition includes 2# and 2! subunits with an additional single $ or - subunit. Fur-
thermore, GABAARs formed by pentameric assembly of multiple different subunits can be 
targeted to distinct subcellular regions and the expression levels of these GABAARs may vary 
largely due to a receptor subunit composition differences in specific cellular locations (e.g. 
Jacob et al. 2008; Luscher et al. 2011). Also, differently formed GABAARs possess distinct 
pharmacological and physiological properties. For example, a composition containing #1, #2, 
#3 or #5 subunits together with ! and $ subunits are benzodiazepine-sensitive, mainly synap-
tically located and mediate the most of the phasic inhibition in the brain (Brunig et al. 2002). 
By contrast, GABAARs composed of #4 or #6 subunits associated with ! and - subunits are 
insensitive to benzodiazepine modulation. These receptors mediate tonic inhibition in the 
brain and form a distinct population of extrasynaptic (i.e. GABAARs that are not located at 
synaptic sites) receptors. The data from the experiments performed with mature sypatically 
connected cortical neurons suggests that the effect of benzodiazepine-induced increase in tau 
phosphorylation is for the most part mediated by synaptic GABAA receptors. 
 Benzodiazepines (BZ) are commonly used hypnotics, anti-convulsants and anxiolytics that 
are routinely utilized in presurgical anesthesia due to their potent sedative properties. Devel-
opment of tolerance and addiction are both known adverse effects of BZs, which is the reason 
why long-term usage of BZs has not been approved. BZs and ethanol, which are both associ-
ated with anterograde amnesia, shares several pharmacological actions and they both act 
mostly or partially through GABAA receptors (Curran 1991; Fadda & Rossetti 1998). Fur-
thermore, increased tau phosphorylation at PHF-1 epitope and Ser199 has been reported in 
developing neurons induced by ethanol exposure (Saito et al. 2010). The data from the ex-
periments in cultural neurons suggests that tau phosphorylation at the AT8 epitope is a down-
stream effect induced by GABAAR activation and, this phosphorylation further remains at 
elevated level for at least 24 h after the washout of GABAAR activating drugs. These observa-
tions raise intriguing questions of the mechanistic associations between the chronic use of 
sedatives or ethanol, anterograde amnesia, and possibly even increased risk of dementia.  
 Protein phosphatase 2A (PP2A) has been shown to associate with and dephosphorylate 
GABAAR subunit !3, a subunit which phosphorylation appears to play an important role in 
the regulation of GABAAR function (Jovanovic et al. 2004). The data presented here suggests 
that activation of GABAARs enhances tau phosphorylation and increases tau-Pin1 interaction 
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but decreases the association between PP2A and tau. Furthermore, based on the PP2A phos-
photase activity assay, the enzyme activity of PP2A is not inhibited directly by GABAAR 
modulators in vitro. However, the tau-PP2A PCA data showed a decrease in the interaction 
when treated with GABAAR-active sedatives, which may at least partly result from the com-
partment-specific differences in PP2A expression and enzyme activity due to the polarized 
structure of neuronal cells. Hence, the recruitment of PP2A for GABAAR !3 subunit dephos-
phorylation and receptor desensitization that is possibly induced by strong and persistent 
GABAA receptor activation, could reduce the PP2A availability to dephosphorylate tau. 
Moreover, the association of synaptic activity, PP2A and their contribution to tau phosphory-
lation has been further studied. It has been suggested that synaptically released zinc could 
play an important role in tau hyperphosphorylation (Sun et al. 2012). It was shown that in 
cultured hippocampal slices and primary neurons, the blockade of zinc release in the synaptic 
terminals highly decreased the tau hyperphosphorylation associated to synaptic activity and, 
also, that synaptic activity-induced hyperphosphorylation was strongly associated to PP2A 
inactivation. The suggestion that increased phosphorylation of tau is induced by synaptically 
released zinc through inhibition of PP2A, which was actually reported to be reversed by zinc 
chelators, provides another implication between synaptic activity and deregulation of tau 
phosphorylation. However, whether the synaptic activity contributes to deregulation of tau 
phosphorylation or is a merely another physiological tau function remains to be clarified by 
future studies. 
7.2 Conclusions and future experiments 
Regulation of tau phosphorylation and dephosphorylation is a highly controlled event in neu-
rons. Disturbed equilibrium of this dynamic system may contribute to development of various 
tauopathies, such as Alzheimer’s disease and frontotemperal dementia. Therefore, more de-
tailed understanding of the highly complex dynamics of protein-protein interactions of tau is 
required to respond to the emerging need to develop novel tau-targeted therapies for aging-
related CNS disorders. However, different approaches have been used in order to identify 
compounds or molecules that could potentially modulate tau phosphorylation from a disease-
modifying aspect regarding to neurodegenerative diseases (e.g. Ballatore et al. 2007).  
 In conclusion, based on the data presented here, PCA-based novel dynamic assay is a 
method capable for measuring protein-protein interactions of tau in live cells. Validation of 
the assay showed that Pin1-tau interaction is responding to both pharmacological and genetic 
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modulation thereby confirming its feasibility and reliability to further investigate tau interac-
tions and search for possible novel molecules and compounds to decrease or increase specific 
tau PPIs. After the parameter validations, the proof-of-concept screening was performed using 
the focused libraries of pharmaceutical and natural compounds. The hits from the screen iden-
tified a class of physiologically relevant compounds belonging to GABAA active drugs. The 
effect of these benzodiazepines and barbiturates were further studied on mature synaptically 
connected cortical neurons confirming an increase in tau phosphorylation. Moreover, desal-
kylflurazepam and butethel induced the phosphorylation of tau at the AT8 epitope 
(Ser199/Ser202/Thr205) as a downstream effect of GABAA receptor activation and the phos-
phorylation remained at an elevated level for at least 24 h after the washout of the drugs. In-
terestingly, the tau-PP2A interaction was decreased when treated with desalkylflurazepam 
and butethal. However, this effect is not directly mediated by the inhibition of PP2A enzyme 
activity in a cell free assay.  
 The exact mechanism how GABAA receptor activation is associated to the observed in-
crease in tau phosphorylation is yet to be established. The major inhibitory synapse scaffold-
ing protein gephyrin that is directly linked to microtubules associates with GABAAR com-
plexes (Prior et al. 1992; Essrich et al. 1998). As a highly abundant MT-binding protein, tau 
could also play a role in a dynamic process of clustering regulation or contribute to trafficking 
of GABAARs at the inhibitory synaptic sites. Moreover, tau may consequently become a sub-
ject of modulation by GABAergic synaptic signaling, which could be manifested as an aber-
rant phosphorylation. Furthermore, the investigation if tau and gephyrin are directly or indi-
rectly connected could bring novel insights about the GABAAR clustering and trafficking.  
 The regulation of tau phosphorylation per se is a highly complex system, which is affected 
by multiple protein kinases and phosphatases. Although GSK-3! and CDK5 have been re-
ferred as major kinases in tau phosphorylation, more detailed understanding is required about 
the contribution of other kinases and their priming kinase effects on phosphorylation, and, 
also on the temporal sequence of phosphorylation and how it is affected by the primed phos-
phosites. In addition to phosphorylation, numerous other post-translational modifications, 
such as glycosylation and acetylation, regulate tau function. Hence, the overall impact of the 
numerous possible tau modifications needs more detailed investigation in order to establish 
the potential tau species that contribute to neurodegeneration of multiple tauopathies. 
 A growing number of reports from e.g. amyloid-! peptide targeted clinical trial discon-
tunuations sets more and more emphasis to alternative approaches to treat and diagnose AD 
and other related forms of dementia. An emerging field of identifying biomarkers for specific 
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diseases is essential for earlier diagnosis of neurodegenerative disorders (ND). Because the 
asymptomatic stage of certain NDs can last for years or even decades before the clinical mani-
festation, the early diagnosis, or at least exclusion of related disorder, is instrumental to search 
for novel symptomatic, neuroprotective or even disease-modifying therapeutics. Interestingly, 
besides the conventional role of tau as a cytoskeletal stabilizer protein, novel functions of tau 
have been described. For example, it has been suggested that hyperphosphorylation-induced 
dendritic (mis)localization of tau may directly promote synaptic dysfunction in the dendritic 
spines (Hoover et al. 2010) and induce synaptotoxicity of !-amyloid via the NMDA receptor 
which is associated to Fyn transport in dendritic postsynapse (Ittner et al. 2010). These in-
triguing novel aspects of tau function and dysfunction further substantiate the importance to 
study tau-driven neurodegeneration in tauopathies for more extensive understanding and tar-
geted therapeutics of these disorders. Importantly, idiopathic neurodegenerative disorders are 
not generally manifestations of a single disease-specific predominant protein but combina-
tions of concurrent and concomitant pathophysiological processes that eventually lead to neu-
rodegeneration and subsequent disease-specific symptoms.     
ACKNOWLEDGEMENTS 
I would like to thank my supervisor, Dr. Henri Huttunen, and all the people who contributed 
to this work: Kai Kysenius and Prasanna Sakha from Neuroscience Center and Dr. Päivi 
Tammela from Center of Drug Research, Faculty of Pharmacy, University of Helsinki. The 
facilities and equipment used in this work were provided by Neuroscience Center, University 
of Helsinki. This work was funded by Sigrid Juselius Foundation and Academy of Finland.  
REFERENCES 
Agarwal-Mawal, A., Qureshi, H.Y., Cafferty, P.W., Yuan, Z., Han, D., Lin, R. & Paudel, 
H.K. 2003: 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtu-
bule-associated tau phosphorylation complex. – The Journal of Biological Chemistry 278: 
12722-12728.  
Ahn, K.J., Jeong, H.K., Choi, H.S., Ryoo, S.R., Kim, Y.J., Goo, J.S., Choi, S.Y., Han, J.S., 
Ha, I. & Song, W.J. 2006: DYRK1A BAC transgenic mice show altered synaptic plasticity 
with learning and memory defects. – Neurobiology of Disease 22: 463-472.  
Alonso Adel, C., Mederlyova, A., Novak, M., Grundke-Iqbal, I. & Iqbal, K. 2004: Promotion 
of hyperphosphorylation by frontotemporal dementia tau mutations. – The Journal of Bio-
logical Chemistry 279: 34873-34881.  
Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. 2001a: Hyperphosphorylation 
induces self-assembly of tau into tangles of paired helical filaments/straight filaments. – 
Proceedings of the National Academy of Sciences of the United States of America 98: 
6923-6928.  
 55!
Alonso, A.C., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. 1994: Role of abnormally phosphoryla-
ted tau in the breakdown of microtubules in Alzheimer disease. – Proceedings of the Na-
tional Academy of Sciences of the United States of America 91: 5562-5566.  
Alonso, A.D., Di Clerico, J., Li, B., Corbo, C.P., Alaniz, M.E., Grundke-Iqbal, I. & Iqbal, K. 
2010: Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurode-
generation. – The Journal of Biological Chemistry 285: 30851-30860.  
Alonso, A.D., Grundke-Iqbal, I., Barra, H.S. & Iqbal, K. 1997: Abnormal phosphorylation of 
tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of micro-
tubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal 
tau. – Proceedings of the National Academy of Sciences of the United States of America 
94: 298-303.  
Alonso, A.D., Zaidi, T., Novak, M., Barra, H.S., Grundke-Iqbal, I. & Iqbal, K. 2001b: Interac-
tion of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in 
vitro phosphorylation into the disease-like protein. – The Journal of Biological Chemistry 
276: 37967-37973.  
Amos, L.A. 2004: Microtubule structure and its stabilisation. – Organic & Biomolecular 
Chemistry 2: 2153-2160.  
Andreadis, A., Broderick, J.A. & Kosik, K.S. 1995: Relative exon affinities and suboptimal 
splice site signals lead to non-equivalence of two cassette exons. – Nucleic Acids Research 
23: 3585-3593.  
Andreadis, A., Brown, W.M. & Kosik, K.S. 1992: Structure and novel exons of the human tau 
gene. – Biochemistry 31: 10626-10633.  
Arendt, T., Stieler, J., Strijkstra, A.M., Hut, R.A., Rudiger, J., Van der Zee, E.A., Harkany, T., 
Holzer, M. & Hartig, W. 2003: Reversible paired helical filament-like phosphorylation of 
tau is an adaptive process associated with neuronal plasticity in hibernating animals. – The 
Journal of Neuroscience 23: 6972-6981.  
Arkin, M.R. & Wells, J.A. 2004: Small-molecule inhibitors of protein-protein interactions: 
progressing towards the dream. – Nature Reviews Drug Discovery 3: 301-317.  
Arnold, C.S., Johnson, G.V., Cole, R.N., Dong, D.L., Lee, M. & Hart, G.W. 1996: The micro-
tubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. 
– The Journal of Biological Chemistry 271: 28741-28744.  
Avila, J., Wandosell, F. & Hernandez, F. 2010: Role of glycogen synthase kinase-3 in Al-
zheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. – Expert Review 
of Neurotherapeutics 10: 703-710.  
Ballatore, C., Lee, V.M. & Trojanowski, J.Q. 2007: Tau-mediated neurodegeneration in Al-
zheimer's disease and related disorders. – Nature Reviews Neuroscience 8: 663-672.  
Baraldi, M., Guidotti, A., Schwartz, J.P. & Costa, E. 1979: GABA receptors in clonal cell 
lines: a model for study of benzodiazepine action at molecular level. – Science 205: 821-
823.  
Bertrand, J., Plouffe, V., Senechal, P. & Leclerc, N. 2010: The pattern of human tau phospho-
rylation is the result of priming and feedback events in primary hippocampal neurons. – 
Neuroscience 168: 323-334.  
Brady, R.M., Zinkowski, R.P. & Binder, L.I. 1995: Presence of tau in isolated nuclei from 
human brain. – Neurobiology of Aging 16: 479-486.  
Brandt, R., Leger, J. & Lee, G. 1995: Interaction of tau with the neural plasma membrane 
mediated by tau's amino-terminal projection domain. – The Journal of Cell Biology 131: 
1327-1340.  
Brunden, K.R., Trojanowski, J.Q. & Lee, V.M. 2008: Evidence that non-fibrillar tau causes 
pathology linked to neurodegeneration and behavioral impairments. – Journal of Al-
zheimer’s Disease 14: 393-399.  
 56!
Brunig, I., Scotti, E., Sidler, C. & Fritschy, J.M. 2002: Intact sorting, targeting, and clustering 
of gamma-aminobutyric acid A receptor subtypes in hippocampal neurons in vitro. – The 
Journal of Comparative Neurology 443: 43-55.  
Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. & Hof, P.R. 2000: Tau protein iso-
forms, phosphorylation and role in neurodegenerative disorders. – Brain Researchearch 
Reviews 33: 95-130.  
Bulbarelli, A., Lonati, E., Cazzaniga, E., Gregori, M. & Masserini, M. 2009: Pin1 affects Tau 
phosphorylation in response to Abeta oligomers. – Molecular and Cellular Neuroscience 
42: 75-80.  
Chau, M.F., Radeke, M.J., de Ines, C., Barasoain, I., Kohlstaedt, L.A. & Feinstein, S.C. 1998: 
The microtubule-associated protein tau cross-links to two distinct sites on each alpha and 
beta tubulin monomer via separate domains. – Biochemistry 37: 17692-17703.  
Cho, J.H. & Johnson, G.V. 2003: Glycogen synthase kinase 3beta phosphorylates tau at both 
primed and unprimed sites. Differential impact on microtubule binding. – The Journal of 
Biological Chemistry 278: 187-193.  
Churcher, I. 2006: Tau therapeutic strategies for the treatment of Alzheimer's disease. – Cur-
rent Topics in Medicinal Chemistry 6: 579-595.  
Cohen, T.J., Guo, J.L., Hurtado, D.E., Kwong, L.K., Mills, I.P., Trojanowski, J.Q. & Lee, 
V.M. 2011: The acetylation of tau inhibits its function and promotes pathological tau ag-
gregation. – Nature Communications 2: 252.  
Corcoran, N.M., Martin, D., Hutter-Paier, B., Windisch, M., Nguyen, T., Nheu, L., Sundst-
rom, L.E., Costello, A.J. & Hovens, C.M. 2010: Sodium selenate specifically activates 
PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's 
disease model. – Journal of Clinical Neuroscience 17: 1025-1033.  
Cripps, D., Thomas, S.N., Jeng, Y., Yang, F., Davies, P. & Yang, A.J. 2006: Alzheimer di-
sease-specific conformation of hyperphosphorylated paired helical filament-Tau is poly-
ubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. – The Journal of 
Biological Chemistry 281: 10825-10838.  
Cruz, J.C. & Tsai, L.H. 2004a: A Jekyll and Hyde kinase: roles for Cdk5 in brain develop-
ment and disease. – Current Opinion in Neurobiology 14: 390-394.  
Cruz, J.C. & Tsai, L.H. 2004b: Cdk5 deregulation in the pathogenesis of Alzheimer's disease. 
– Trends in Molecular Medicine 10: 452-458.  
Curran, H.V. 1991: Benzodiazepines, memory and mood: a review. – Psychopharmacology 
(Berl) 105: 1-8.  
Delobel, P., Flament, S., Hamdane, M., Mailliot, C., Sambo, A.V., Begard, S., Sergeant, N., 
Delacourte, A., Vilain, J.P. & Buee, L. 2002: Abnormal Tau phosphorylation of the Al-
zheimer-type also occurs during mitosis. – Journal of Neurochemistry 83: 412-420.  
Essrich, C., Lorez, M., Benson, J.A., Fritschy, J.M. & Luscher, B. 1998: Postsynaptic cluste-
ring of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin. – 
Nature Neuroscience 1: 563-571.  
Fadda, F. & Rossetti, Z.L. 1998: Chronic ethanol consumption: from neuroadaptation to neu-
rodegeneration. – Progress in Neurobiology 56: 385-431.  
Fu, H., Subramanian, R.R. & Masters, S.C. 2000: 14-3-3 proteins: structure, function, and 
regulation. – Annual Review of Pharmacology and Toxicology 40: 617-647.  
Garcia de Ancos, J., Correas, I. & Avila, J. 1993: Differences in microtubule binding and self-
association abilities of bovine brain tau isoforms. – The Journal of Biological Chemistry 
268: 7976-7982.  
Glatz, D.C., Rujescu, D., Tang, Y., Berendt, F.J., Hartmann, A.M., Faltraco, F., Rosenberg, 
C., Hulette, C., Jellinger, K., Hampel, H., Riederer, P., Moller, H.J., Andreadis, A., Hen-
kel, K. & Stamm, S. 2006: The alternative splicing of tau exon 10 and its regulatory pro-
 57!
teins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. – Journal of Neu-
rochemistry 96: 635-644.  
Goedert, M. & Jakes, R. 2005: Mutations causing neurodegenerative tauopathies. – Biochimi-
ca et Biophysica Acta 1739: 240-250.  
Goedert, M., Jakes, R., Crowther, R.A., Six, J., Lubke, U., Vandermeeren, M., Cras, P., Tro-
janowski, J.Q. & Lee, V.M. 1993: The abnormal phosphorylation of tau protein at Ser-202 
in Alzheimer disease recapitulates phosphorylation during development. – Proceedings of 
the National Academy of Sciences of the United States of America 90: 5066-5070.  
Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D. & Crowther, R.A. 1989a: Multiple 
isoforms of human microtubule-associated protein tau: sequences and localization in neu-
rofibrillary tangles of Alzheimer's disease. – Neuron 3: 519-526.  
Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J. & Crowther, R.A. 1989b: Cloning and 
sequencing of the cDNA encoding an isoform of microtubule-associated protein tau con-
taining four tandem repeats: differential expression of tau protein mRNAs in human brain. 
– The EMBO Journal 8: 393-399.  
Gong, C.X. & Iqbal, K. 2008: Hyperphosphorylation of microtubule-associated protein tau: a 
promising therapeutic target for Alzheimer disease. – Current Medicinal Chemistry 15: 
2321-2328.  
Gong, C.X., Liu, F., Grundke-Iqbal, I. & Iqbal, K. 2005: Post-translational modifications of 
tau protein in Alzheimer's disease. – Journal of Neural Transmission 112: 813-838.  
Goode, B.L. & Feinstein, S.C. 1994: Identification of a novel microtubule binding and as-
sembly domain in the developmentally regulated inter-repeat region of tau. – The Journal 
of Cell Biology 124: 769-782.  
Grimes, C.A. & Jope, R.S. 2001: The multifaceted roles of glycogen synthase kinase 3beta in 
cellular signaling. – Progress in Neurobiology 65: 391-426.  
Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M. & Binder, L.I. 1986: 
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cy-
toskeletal pathology. – Proceedings of the National Academy of Sciences of the United 
States of America 83: 4913-4917.  
Hashiguchi, M., Sobue, K. & Paudel, H.K. 2000: 14-3-3zeta is an effector of tau protein 
phosphorylation. – The Journal of Biological Chemistry 275: 25247-25254.  
Hennig, L., Christner, C., Kipping, M., Schelbert, B., Rucknagel, K.P., Grabley, S., Kullertz, 
G. & Fischer, G. 1998: Selective inactivation of parvulin-like peptidyl-prolyl cis/trans iso-
merases by juglone. – Biochemistry 37: 5953-5960.  
Hernandez, F. & Avila, J. 2007: Tauopathies. – Cellular and Molecular Life Sciences 64: 
2219-2233.  
Hernandez, F., Cuadros, R. & Avila, J. 2004: Zeta 14-3-3 protein favours the formation of 
human tau fibrillar polymers. – Neuroscience Letters 357: 143-146.  
Himpel, S., Panzer, P., Eirmbter, K., Czajkowska, H., Sayed, M., Packman, L.C., Blundell, 
T., Kentrup, H., Grotzinger, J., Joost, H.G. & Becker, W. 2001: Identification of the au-
tophosphorylation sites and characterization of their effects in the protein kinase 
DYRK1A. – Biochemical Journal 359: 497-505.  
Himpel, S., Tegge, W., Frank, R., Leder, S., Joost, H.G. & Becker, W. 2000: Specificity de-
terminants of substrate recognition by the protein kinase DYRK1A. – The Journal of Bio-
logical Chemistry 275: 2431-2438.  
Hirokawa, N., Shiomura, Y. & Okabe, S. 1988: Tau proteins: the molecular structure and mo-
de of binding on microtubules. – The Journal of Cell Biology 107: 1449-1459.  
Hong, M. 1998: Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Here-
ditary FTDP-17. – Science 282: 1914-1917.  
 58!
Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., 
Carlson, G.A., Lanier, L.M., Yuan, L.L., Ashe, K.H. & Liao, D. 2010: Tau mislocalization 
to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. – 
Neuron 68: 1067-1081.  
Horiguchi, T., Uryu, K., Giasson, B.I., Ischiropoulos, H., LightFoot, R., Bellmann, C., Rich-
ter-Landsberg, C., Lee, V.M. & Trojanowski, J.Q. 2003: Nitration of tau protein is linked 
to neurodegeneration in tauopathies. – The American Journal of Pathology 163: 1021-
1031.  
Hu, C.D., Chinenov, Y. & Kerppola, T.K. 2002: Visualization of interactions among bZIP 
and Rel family proteins in living cells using bimolecular fluorescence complementation. – 
Molecular Cell 9: 789-798.  
Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, 
S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, 
D., Davies, P., Petersen, R.C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hille-
brand, M., Joosse, M., Kwon, J.M., Nowotny, P., Che, L.K., Norton, J., Morris, J.C., Reed, 
L.A., Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., Dark, F., Tannenberg, 
T., Dodd, P.R., Hayward, N., Kwok, J.B., Schofield, P.R., Andreadis, A., Snowden, J., 
Craufurd, D., Neary, D., Owen, F., Oostra, B.A., Hardy, J., Goate, A., van Swieten, J., 
Mann, D., Lynch, T. & Heutink, P. 1998: Association of missense and 5'-splice-site muta-
tions in tau with the inherited dementia FTDP-17. – Nature 393: 702-705.  
Iqbal, K., Alonso Adel, C., Chen, S., Chohan, M.O., El-Akkad, E., Gong, C.X., Khatoon, S., 
Li, B., Liu, F., Rahman, A., Tanimukai, H. & Grundke-Iqbal, I. 2005: Tau pathology in 
Alzheimer disease and other tauopathies. – Biochimica et Biophysica Acta 1739: 198-210.  
Iqbal, K., Grundke-Iqbal, I., Smith, A.J., George, L., Tung, Y.C. & Zaidi, T. 1989: Identifica-
tion and localization of a tau peptide to paired helical filaments of Alzheimer disease. – 
Proceedings of the National Academy of Sciences of the United States of America 86: 
5646-5650.  
Iqbal, K., Liu, F., Gong, C.X., Alonso Adel, C. & Grundke-Iqbal, I. 2009: Mechanisms of 
tau-induced neurodegeneration. – Acta Neuropathologica 118: 53-69.  
Irwin, D.J., Cohen, T.J., Grossman, M., Arnold, S.E., Xie, S.X., Lee, V.M. & Trojanowski, 
J.Q. 2012: Acetylated tau, a novel pathological signature in Alzheimer's disease and other 
tauopathies. – Brain 135: 807-818.  
Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wolfing, H., Chieng, 
B.C., Christie, M.J., Napier, I.A., Eckert, A., Staufenbiel, M., Hardeman, E. & Gotz, J. 
2010: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease 
mouse models. – Cell 142: 387-397.  
Jacob, T.C., Moss, S.J. & Jurd, R. 2008: GABA(A) receptor trafficking and its role in the 
dynamic modulation of neuronal inhibition. – Nature Reviews Neuroscience 9: 331-343.  
Jope, R.S. & Johnson, G.V. 2004: The glamour and gloom of glycogen synthase kinase-3. – 
Trends in Biochemical Sciences 29: 95-102.  
Jovanovic, J.N., Thomas, P., Kittler, J.T., Smart, T.G. & Moss, S.J. 2004: Brain-derived neu-
rotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor 
phosphorylation, activity, and cell-surface stability. – The Journal of Neuroscience 24: 
522-530.  
Kampers, T., Friedhoff, P., Biernat, J., Mandelkow, E.M. & Mandelkow, E. 1996: RNA sti-
mulates aggregation of microtubule-associated protein tau into Alzheimer-like paired heli-
cal filaments. – FEBS Letters 399: 344-349.  
Kar, S., Fan, J., Smith, M.J., Goedert, M. & Amos, L.A. 2003: Repeat motifs of tau bind to 
the insides of microtubules in the absence of taxol. – The EMBO Journal 22: 70-77.  
 59!
Kelleher, I., Garwood, C., Hanger, D.P., Anderton, B.H. & Noble, W. 2007: Kinase activities 
increase during the development of tauopathy in htau mice. – Journal of Neurochemistry 
103: 2256-2267.  
Keller, J.N., Hanni, K.B. & Markesbery, W.R. 2000: Impaired proteasome function in Al-
zheimer's disease. – Journal of Neurochemistry 75: 436-439.  
Kim, D., Won, J., Shin, D.W., Kang, J., Kim, Y.J., Choi, S.Y., Hwang, M.K., Jeong, B.W., 
Kim, G.S., Joe, C.O., Chung, S.H. & Song, W.J. 2004: Regulation of Dyrk1A kinase acti-
vity by 14-3-3. – Biochemical and Biophysical Research Communications 323: 499-504.  
Kim, E.K. & Choi, E.J. 2010: Pathological roles of MAPK signaling pathways in human di-
seases. – Biochimica et Biophysica Acta 1802: 396-405.  
Kopke, E., Tung, Y.C., Shaikh, S., Alonso, A.C., Iqbal, K. & Grundke-Iqbal, I. 1993: Micro-
tubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament 
pool in Alzheimer disease. – The Journal of Biological Chemistry 268: 24374-24384.  
Kosik, K.S., Orecchio, L.D., Bakalis, S. & Neve, R.L. 1989: Developmentally regulated ex-
pression of specific tau sequences. – Neuron 2: 1389-1397.  
Kuhla, B., Haase, C., Flach, K., Luth, H.J., Arendt, T. & Munch, G. 2007: Effect of pseu-
dophosphorylation and cross-linking by lipid peroxidation and advanced glycation end 
product precursors on tau aggregation and filament formation. – The Journal of Biological 
Chemistry 282: 6984-6991.  
Kuret, J., Johnson, G.S., Cha, D., Christenson, E.R., DeMaggio, A.J. & Hoekstra, M.F. 1997: 
Casein kinase 1 is tightly associated with paired-helical filaments isolated from Al-
zheimer's disease brain. – Journal of Neurochemistry 69: 2506-2515.  
Kusakawa, G., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T. & Hisanaga, S. 2000: Cal-
pain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. 
– The Journal of Biological Chemistry 275: 17166-17172.  
Lebel, M. & Cyr, M. 2011: Molecular and cellular events of dopamine D1 receptor-mediated 
tau phosphorylation in SK-N-MC cells. – Synapse 65: 69-76.  
Lebel, M., Patenaude, C., Allyson, J., Massicotte, G. & Cyr, M. 2009: Dopamine D1 receptor 
activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. – Neu-
ropharmacology 57: 392-402.  
Lee, G., Neve, R.L. & Kosik, K.S. 1989: The microtubule binding domain of tau protein. – 
Neuron 2: 1615-1624.  
Lee, G., Thangavel, R., Sharma, V.M., Litersky, J.M., Bhaskar, K., Fang, S.M., Do, L.H., 
Andreadis, A., Van Hoesen, G. & Ksiezak-Reding, H. 2004: Phosphorylation of tau by 
fyn: implications for Alzheimer's disease. – The Journal of Neuroscience 24: 2304-2312.  
Lee, V.M., Goedert, M. & Trojanowski, J.Q. 2001: Neurodegenerative tauopathies. – Annual 
Review of Neuroscience 24: 1121-1159.  
Lembert, N. & Idahl, L.A. 1995: Regulatory effects of ATP and luciferin on firefly luciferase 
activity. – Biochemical Journal 305: 929-933.  
Lew, J., Huang, Q.Q., Qi, Z., Winkfein, R.J., Aebersold, R., Hunt, T. & Wang, J.H. 1994: A 
brain-specific activator of cyclin-dependent kinase 5. – Nature 371: 423-426.  
Li, H.L., Wang, H.H., Liu, S.J., Deng, Y.Q., Zhang, Y.J., Tian, Q., Wang, X.C., Chen, X.Q., 
Yang, Y., Zhang, J.Y., Wang, Q., Xu, H., Liao, F.F. & Wang, J.Z. 2007: Phosphorylation 
of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Al-
zheimer's neurodegeneration. – Proceedings of the National Academy of Sciences of the 
United States of America 104: 3591-3596.  
Li, L., Sengupta, A., Haque, N., Grundke-Iqbal, I. & Iqbal, K. 2004: Memantine inhibits and 
reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neuro-
degeneration. – FEBS Letters 566: 261-269.  
 60!
Liou, Y.C., Ryo, A., Huang, H.K., Lu, P.J., Bronson, R., Fujimori, F., Uchida, T., Hunter, T. 
& Lu, K.P. 2002: Loss of Pin1 function in the mouse causes phenotypes resembling cyclin 
D1-null phenotypes. – Proceedings of the National Academy of Sciences of the United Sta-
tes of America 99: 1335-1340.  
Liou, Y.C., Sun, A., Ryo, A., Zhou, X.Z., Yu, Z.X., Huang, H.K., Uchida, T., Bronson, R., 
Bing, G., Li, X., Hunter, T. & Lu, K.P. 2003: Role of the prolyl isomerase Pin1 in protec-
ting against age-dependent neurodegeneration. – Nature 424: 556-561.  
Liu, F., Grundke-Iqbal, I., Iqbal, K. & Gong, C.X. 2005: Contributions of protein phospha-
tases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. – European 
Journal of Neuroscience 22: 1942-1950.  
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G.W. & Gong, C.X. 2004: O-GlcNAcylation regu-
lates phosphorylation of tau: a mechanism involved in Alzheimer's disease. – Proceedings 
of the National Academy of Sciences of the United States of America 101: 10804-10809.  
Liu, F., Li, B., Tung, E.J., Grundke-Iqbal, I., Iqbal, K. & Gong, C.X. 2007: Site-specific ef-
fects of tau phosphorylation on its microtubule assembly activity and self-aggregation. – 
European Journal of Neuroscience 26: 3429-3436.  
Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I. & Gong, C.X. 2002a: Aberrant glycosylation 
modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by 
protein phosphatase 2A and 5. – Neuroscience 115: 829-837.  
Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I., Merkle, R.K. & Gong, C.X. 2002b: Role of 
glycosylation in hyperphosphorylation of tau in Alzheimer's disease. – FEBS Letters 512: 
101-106.  
Liu, S.J., Zhang, A.H., Li, H.L., Wang, Q., Deng, H.M., Netzer, W.J., Xu, H. & Wang, J.Z. 
2003: Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 ki-
nase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial 
memory. – Journal of Neurochemistry 87: 1333-1344.  
Liu, S.J., Zhang, J.Y., Li, H.L., Fang, Z.Y., Wang, Q., Deng, H.M., Gong, C.X., Grundke-
Iqbal, I., Iqbal, K. & Wang, J.Z. 2004: Tau becomes a more favorable substrate for GSK-3 
when it is prephosphorylated by PKA in rat brain. – The Journal of Biological Chemistry 
279: 50078-50088.  
Lu, K.P. 2004: Pinning down cell signaling, cancer and Alzheimer's disease. – Trends in 
Biochemical Sciences 29: 200-209.  
Lu, K.P., Hanes, S.D. & Hunter, T. 1996: A human peptidyl-prolyl isomerase essential for 
regulation of mitosis. – Nature 380: 544-547.  
Lu, K.P., Liou, Y.C. & Zhou, X.Z. 2002: Pinning down proline-directed phosphorylation sig-
naling. – Trends in Cell Biology 12: 164-172.  
Lu, M. & Kosik, K.S. 2001: Competition for microtubule-binding with dual expression of tau 
missense and splice isoforms. – Molecular Biology of the Cell 12: 171-184.  
Lu, P.J., Wulf, G., Zhou, X.Z., Davies, P. & Lu, K.P. 1999: The prolyl isomerase Pin1 resto-
res the function of Alzheimer-associated phosphorylated tau protein. – Nature 399: 784-
788.  
Lu, P.J., Zhou, X.Z., Liou, Y.C., Noel, J.P. & Lu, K.P. 2002: Critical role of WW domain 
phosphorylation in regulating phosphoserine binding activity and Pin1 function. – The 
Journal of Biological Chemistry 277: 2381-2384.  
Luchsinger, J.A., Tang, M.X., Miller, J., Green, R. & Mayeux, R. 2007: Relation of higher 
folate intake to lower risk of Alzheimer disease in the elderly. – Archives of Neurology 64: 
86-92.  
Luscher, B., Fuchs, T. & Kilpatrick, C.L. 2011: GABAA receptor trafficking-mediated plasti-
city of inhibitory synapses. – Neuron 70: 385-409.  
 61!
Ma, S.L., Pastorino, L., Zhou, X.Z. & Lu, K.P. 2012: Prolyl isomerase Pin1 promotes amy-
loid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta 
(GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease. – 
The Journal of Biological Chemistry 287: 6969-6973.  
Meraz-Rios, M.A., Lira-De Leon, K.I., Campos-Pena, V., De Anda-Hernandez, M.A. & Me-
na-Lopez, R. 2010: Tau oligomers and aggregation in Alzheimer's disease. – Journal of 
Neurochemistry 112: 1353-1367.  
Michnick, S.W. 2001: Exploring protein interactions by interaction-induced folding of pro-
teins from complementary peptide fragments. – Current Opinion in Structural Biology 11: 
472-477.  
Michnick, S.W., Ear, P.H., Manderson, E.N., Remy, I. & Stefan, E. 2007: Universal strategies 
in research and drug discovery based on protein-fragment complementation assays. – Na-
ture Reviews Drug Discovery 6: 569-582.  
Michnick, S.W., Remy, I., Campbell-Valois, F.X., Vallee-Belisle, A. & Pelletier, J.N. 2000: 
Detection of protein-protein interactions by protein fragment complementation strategies. – 
Methods in Enzymology 328: 208-230.  
Min, S.W., Cho, S.H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W.W., Huang, E.J., 
Shen, Y., Masliah, E., Mukherjee, C., Meyers, D., Cole, P.A., Ott, M. & Gan, L. 2010: 
Acetylation of tau inhibits its degradation and contributes to tauopathy. – Neuron 67: 953-
966.  
Munoz, L. & Ammit, A.J. 2010: Targeting p38 MAPK pathway for the treatment of Al-
zheimer's disease. – Neuropharmacology 58: 561-568.  
Neve, R.L., Harris, P., Kosik, K.S., Kurnit, D.M. & Donlon, T.A. 1986: Identification of 
cDNA clones for the human microtubule-associated protein tau and chromosomal localiza-
tion of the genes for tau and microtubule-associated protein 2. – Brain Research 387: 271-
280.  
Park, J., Song, W.J. & Chung, K.C. 2009: Function and regulation of Dyrk1A: towards un-
derstanding Down syndrome. – Cellular and Molecular Life Sciences 66: 3235-3240.  
Pastorino, L., Sun, A., Lu, P.J., Zhou, X.Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.H., 
Li, X., Xia, W., Nicholson, L.K. & Lu, K.P. 2006: The prolyl isomerase Pin1 regulates 
amyloid precursor protein processing and amyloid-beta production. – Nature 440: 528-534.  
Patrick, G.N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P. & Tsai, L.H. 1999: 
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. – 
Nature 402: 615-622.  
Patzke, H. & Tsai, L.H. 2002: Calpain-mediated cleavage of the cyclin-dependent kinase-5 
activator p39 to p29. – The Journal of Biological Chemistry 277: 8054-8060.  
Perry, G., Friedman, R., Shaw, G. & Chau, V. 1987: Ubiquitin is detected in neurofibrillary 
tangles and senile plaque neurites of Alzheimer disease brains. – Proceedings of the Na-
tional Academy of Sciences of the United States of America 84: 3033-3036.  
Pierrot, N., Santos, S.F., Feyt, C., Morel, M., Brion, J.P. & Octave, J.N. 2006: Calcium-
mediated transient phosphorylation of tau and amyloid precursor protein followed by in-
traneuronal amyloid-beta accumulation. – The Journal of Biological Chemistry 281: 
39907-39914.  
Planel, E., Richter, K.E., Nolan, C.E., Finley, J.E., Liu, L., Wen, Y., Krishnamurthy, P., Her-
man, M., Wang, L., Schachter, J.B., Nelson, R.B., Lau, L.F. & Duff, K.E. 2007: Anesthe-
sia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypot-
hermia. – The Journal of Neuroscience 27: 3090-3097.  
Powell, D.W., Rane, M.J., Chen, Q., Singh, S. & McLeish, K.R. 2002: Identification of 14-3-
3zeta as a protein kinase B/Akt substrate. – The Journal of Biological Chemistry 277: 
21639-21642.  
 62!
Prior, P., Schmitt, B., Grenningloh, G., Pribilla, I., Multhaup, G., Beyreuther, K., Maulet, Y., 
Werner, P., Langosch, D., Kirsch, J. & et, a. 1992: Primary structure and alternative splice 
variants of gephyrin, a putative glycine receptor-tubulin linker protein. – Neuron 8: 1161-
1170.  
Ranganathan, R., Lu, K.P., Hunter, T. & Noel, J.P. 1997: Structural and functional analysis of 
the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. – 
Cell 89: 875-886.  
Remy, I. & Michnick, S.W. 2006: A highly sensitive protein-protein interaction assay based 
on Gaussia luciferase. – Nature Methods 3: 977-979.  
Resh, M.D. 1998: Fyn, a Src family tyrosine kinase. – Int J Biochem Cell Biol 30: 1159-1162.  
Reynolds, M.R., Berry, R.W. & Binder, L.I. 2005: Site-specific nitration and oxidative dity-
rosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. – 
Biochemistry 44: 1690-1700.  
Reynolds, M.R., Reyes, J.F., Fu, Y., Bigio, E.H., Guillozet-Bongaarts, A.L., Berry, R.W. & 
Binder, L.I. 2006: Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's 
disease and other tauopathies. – The Journal of Neuroscience 26: 10636-10645.  
Ryoo, S.R., Cho, H.J., Lee, H.W., Jeong, H.K., Radnaabazar, C., Kim, Y.S., Kim, M.J., Son, 
M.Y., Seo, H., Chung, S.H. & Song, W.J. 2008: Dual-specificity tyrosine(Y)-
phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor pro-
tein: evidence for a functional link between Down syndrome and Alzheimer's disease. – 
Journal of Neurochemistry 104: 1333-1344.  
Ryoo, S.R., Jeong, H.K., Radnaabazar, C., Yoo, J.J., Cho, H.J., Lee, H.W., Kim, I.S., Cheon, 
Y.H., Ahn, Y.S., Chung, S.H. & Song, W.J. 2007: DYRK1A-mediated hyperphosphoryla-
tion of Tau. A functional link between Down syndrome and Alzheimer disease. – The 
Journal of Biological Chemistry 282: 34850-34857.  
Ryu, Y.S., Park, S.Y., Jung, M.S., Yoon, S.H., Kwen, M.Y., Lee, S.Y., Choi, S.H., Radnaaba-
zar, C., Kim, M.K., Kim, H., Kim, K., Song, W.J. & Chung, S.H. 2010: Dyrk1A-mediated 
phosphorylation of Presenilin 1: a functional link between Down syndrome and Al-
zheimer's disease. – Journal of Neurochemistry 115: 574-584.  
Sadik, G., Tanaka, T., Kato, K., Yamamori, H., Nessa, B.N., Morihara, T. & Takeda, M. 
2009: Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: impli-
cations for the mechanism of tau aggregation. – Journal of Neurochemistry 108: 33-43.  
Saito, M., Chakraborty, G., Mao, R.F., Paik, S.M., Vadasz, C. & Saito, M. 2010: Tau 
phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing 
mouse brain. – Neurochemical Research 35: 651-659.  
Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., Koike, T., Wa-
kayama, I., Yanagihara, R., Garruto, R., Amano, N. & Makita, Z. 1998: Advanced glycati-
on end products in Alzheimer's disease and other neurodegenerative diseases. – The Ame-
rican Journal of Pathology 153: 1149-1155.  
Schaeffer, H.J. & Weber, M.J. 1999: Mitogen-activated protein kinases: specific messages 
from ubiquitous messengers. – Molecular and Cellular Biology 19: 2435-2444.  
Sheng, J.G., Jones, R.A., Zhou, X.Q., McGinness, J.M., Van Eldik, L.J., Mrak, R.E. & Grif-
fin, W.S. 2001: Interleukin-1 promotion of MAPK-p38 overexpression in experimental 
animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. 
– Neurochemistry International 39: 341-348.  
Shi, J., Zhang, T., Zhou, C., Chohan, M.O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y.W., Iqbal, 
K., Grundke-Iqbal, I., Gong, C.X. & Liu, F. 2008: Increased dosage of Dyrk1A alters al-
ternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. – 
The Journal of Biological Chemistry 283: 28660-28669.  
 63!
Sontag, J.M., Nunbhakdi-Craig, V., Montgomery, L., Arning, E., Bottiglieri, T. & Sontag, E. 
2008: Folate deficiency induces in vitro and mouse brain region-specific downregulation 
of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit ex-
pression that correlate with enhanced tau phosphorylation. – The Journal of Neuroscience 
28: 11477-11487.  
Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A. & Ghetti, B. 1998: Mu-
tation in the tau gene in familial multiple system tauopathy with presenile dementia. – Pro-
ceedings of the National Academy of Sciences of the United States of America 95: 7737-
7741.  
Sun, X.Y., Wei, Y.P., Xiong, Y., Wang, X.C., Xie, A.J., Wang, X.L., Yang, Y., Wang, Q., 
Lu, Y.M., Liu, R. & Wang, J.Z. 2012: Synaptic released zinc promotes tau hyperphospho-
rylation by inhibition of protein phosphatase 2A (PP2A). – The Journal of Biological 
Chemistry 287: 11174-11182.  
Tanimukai, H., Grundke-Iqbal, I. & Iqbal, K. 2005: Up-regulation of inhibitors of protein 
phosphatase-2A in Alzheimer's disease. – The American Journal of Pathology 166: 1761-
1771.  
Tannous, B.A., Kim, D.E., Fernandez, J.L., Weissleder, R. & Breakefield, X.O. 2005: Codon-
optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. 
– Molecular Therapy 11: 435-443.  
Tatebayashi, Y., Haque, N., Tung, Y.C., Iqbal, K. & Grundke-Iqbal, I. 2004: Role of tau 
phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. 
– Journal of Cell Science 117: 1653-1663.  
Tian, Q. & Wang, J. 2002: Role of Serine/Threonine Protein Phosphatase in Alzheimer's Di-
sease. – Neurosignals 11: 262-269.  
Tucholski, J., Kuret, J. & Johnson, G.V. 1999: Tau is modified by tissue transglutaminase in 
situ: possible functional and metabolic effects of polyamination. – Journal of Neuroche-
mistry 73: 1871-1880.  
van Eersel, J., Ke, Y.D., Liu, X., Delerue, F., Kril, J.J., Gotz, J. & Ittner, L.M. 2010: Sodium 
selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's 
disease models. – Proceedings of the National Academy of Sciences of the United States of 
America 107: 13888-13893.  
van Hemert, M.J., Steensma, H.Y. & van Heusden, G.P. 2001: 14-3-3 proteins: key regulators 
of cell division, signalling and apoptosis. – Bioessays 23: 936-946.  
Vijayan, S., El-Akkad, E., Grundke-Iqbal, I. & Iqbal, K. 2001: A pool of beta-tubulin is hy-
perphosphorylated at serine residues in Alzheimer disease brain. – FEBS Letters 509: 375-
381.  
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J.Q. & Lee, V.M. 2001: PP2A mRNA 
expression is quantitatively decreased in Alzheimer's disease hippocampus. – Experimental 
Neurology 168: 402-412.  
Walsh, D.A. & Van Patten, S.M. 1994: Multiple pathway signal transduction by the cAMP-
dependent protein kinase. – The FASEB Journal 8: 1227-1236.  
Wang, J.Z., Grundke-Iqbal, I. & Iqbal, K. 2007: Kinases and phosphatases and tau sites in-
volved in Alzheimer neurofibrillary degeneration. – European Journal of Neuroscience 25: 
59-68.  
Wang, J.Z. & Liu, F. 2008: Microtubule-associated protein tau in development, degeneration 
and protection of neurons. – Progress in Neurobiology 85: 148-175.  
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y. & Kirschner, M.W. 1975: A protein factor 
essential for microtubule assembly. – Proceedings of the National Academy of Sciences of 
the United States of America 72: 1858-1862.  
 64!
Williamson, R., Scales, T., Clark, B.R., Gibb, G., Reynolds, C.H., Kellie, S., Bird, I.N., Varn-
dell, I.M., Sheppard, P.W., Everall, I. & Anderton, B.H. 2002: Rapid tyrosine phosphoryla-
tion of neuronal proteins including tau and focal adhesion kinase in response to amyloid-
beta peptide exposure: involvement of Src family protein kinases. – The Journal of Neu-
roscience 22: 10-20.  
Wiseman, F.K., Alford, K.A., Tybulewicz, V.L. & Fisher, E.M. 2009: Down syndrome--
recent progress and future prospects. – Human Molecular Genetics 18: R75-83.  
Woodcock, J.M., Murphy, J., Stomski, F.C., Berndt, M.C. & Lopez, A.F. 2003: The dimeric 
versus monomeric status of 14-3-3zeta is controlled by phosphorylation of Ser58 at the 
dimer interface. – The Journal of Biological Chemistry 278: 36323-36327.  
Woodgett, J.R. 1990: Molecular cloning and expression of glycogen synthase kinase-3/factor 
A. – The EMBO Journal 9: 2431-2438.  
Woods, Y.L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X. & Proud, C.G. 2001: 
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at 
Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a 
glycogen synthase kinase 3-priming kinase. – Biochemical Journal 355: 609-615.  
Yaffe, M.B. 1997: Sequence-Specific and Phosphorylation-Dependent Proline Isomerization: 
A Potential Mitotic Regulatory Mechanism. – Science 278: 1957-1960.  
Yamamoto, H., Yamauchi, E., Taniguchi, H., Ono, T. & Miyamoto, E. 2002: Phosphorylation 
of microtubule-associated protein tau by Ca2+/calmodulin-dependent protein kinase II in 
its tubulin binding sites. – Archives of Biochemistry and Biophysics 408: 255-262.  
Yan, S.D., Chen, X., Schmidt, A.M., Brett, J., Godman, G., Zou, Y.S., Scott, C.W., Caputo, 
C., Frappier, T., Smith, M.A. & et, a. 1994: Glycated tau protein in Alzheimer disease: a 
mechanism for induction of oxidant stress. – Proceedings of the National Academy of 
Sciences of the United States of America 91: 7787-7791.  
Yin, H. & Kuret, J. 2006: C-terminal truncation modulates both nucleation and extension pha-
ses of tau fibrillization. – FEBS Letters 580: 211-215.  
Yoshida, M. 2006: Cellular tau pathology and immunohistochemical study of tau isoforms in 
sporadic tauopathies. – Neuropathology 26: 457-470.  
Yuan, Z., Agarwal-Mawal, A. & Paudel, H.K. 2004: 14-3-3 binds to and mediates phosphory-
lation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase ki-
nase 3beta in the brain. – The Journal of Biological Chemistry 279: 26105-26114.  
Yuzwa, S.A., Shan, X., Macauley, M.S., Clark, T., Skorobogatko, Y., Vosseller, K. & Vocad-
lo, D.J. 2012: Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against ag-
gregation. – Nature Chemical Biology 8: 393-399.  
Zhang, Y., Li, H.L., Wang, D.L., Liu, S.J. & Wang, J.Z. 2006: A transitory activation of pro-
tein kinase-A induces a sustained tau hyperphosphorylation at multiple sites in N2a cells-
imply a new mechanism in Alzheimer pathology. – Journal of Neural Transmission 113: 
1487-1497.  
Zhou, X.W., Gustafsson, J.A., Tanila, H., Bjorkdahl, C., Liu, R., Winblad, B. & Pei, J.J. 
2008: Tau hyperphosphorylation correlates with reduced methylation of protein phospha-
tase 2A. – Neurobiology of Disease 31: 386-394.  
Zhou, X.Z., Kops, O., Werner, A., Lu, P.J., Shen, M., Stoller, G., Kullertz, G., Stark, M., Fi-
scher, G. & Lu, K.P. 2000: Pin1-dependent prolyl isomerization regulates dephosphoryla-
tion of Cdc25C and tau proteins. – Molecular Cell 6: 873-883.  
Zhou, X.Z., Lu, P.J., Wulf, G. & Lu, K.P. 1999: Phosphorylation-dependent prolyl isomeriza-
tion: a novel signaling regulatory mechanism. – Cellular and Molecular Life Sciences 56: 
788-806.  
 65!
Zhu, X., Rottkamp, C.A., Boux, H., Takeda, A., Perry, G. & Smith, M.A. 2000: Activation of 
p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Al-
zheimer disease. – Journal of Neuropathology & Experimental Neurology 59: 880-888.  
 
APPENDICES 
Appendix 1. List of screened pharmaceutical compounds. 
 
Pharmaceutical compounds (PC) 
  
Code Name 
PC001 Acetaminophen, Paracetamol 
PC002 Acetanilide 
PC003 Acetazolamide 
PC004 Acetyleneurea, Acetylene carbamide 
PC005 N-Acetylsulfanilamide  
PC006 Acetylsulfisoxazole 
PC007 L-3-(3,4-Dihydroxyphenyl)alanine, L-DOPA 
PC008 Allobarbital 
PC009 Allylestrenol, 17-Alpha-allylestr-4-en-17-beta-oll 
PC010 p-Aminobenzoic acid 
PC011 4-Aminoantipyrine, Ampyrone 
PC012 Amydricaine hydrochloride 
PC013 4-Alpha-Androstane 
PC014 Antazoline, hydrochloride 
PC015 Antipyrine 
PC016 Arecoline hydrobromide 
PC017 Atenolol 
PC018 Atropine methyl nitrate 
PC019 Bamethan 
PC020 Barbital 
PC021 Barbituric acid 
PC022 Benzalkonium chloride 
PC023 Benzocaine 
PC024 Bromhexine hydrochloride 
PC025 Buclosamide 
PC026 Bunitrolol 
PC027 I-Bunolol 
PC028 Busulfan 
PC029 Butethal 
PC030 Butidrine 
PC031 Butyl 4-Aminobenzoate 
PC032 p-Butylaminobenzoyldimethylaminoethanol, Cainopan, Tetracaine hydrochloride 
PC033 1-Butyl-3-sulfanilylurea, Carbutamide 
PC034 Cainopan, p-Butylaminobenzoyldimethylaminoethanol 
PC035 Calcium pantothenate 
PC036 DL-Camphon, Campher (synth.) 
PC037 Carbamazepine 
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PC038 Carteolol hydrochloride 
PC039 Cetrimonium bromide 
PC040 Chloramphenicol 
PC041 Chlordiazepoxide 
PC042 Chlorobutanol 
PC043 4-Chloro-7-nitrobenz-2-oxa-1,3-diazole 
PC044 Chloroquine diphosphate 
PC045 Chlorothiazide 
PC046 Chlorpromazine hydrochloride 
PC047 Chlorprothixene hydrochloride 
PC048 Cinchophen 
PC049 Clioquinol 
PC050 Clopenthixol dihydrochloride 
PC051 Clorprenaline hydrochloride 
PC052 Cornecaine 
PC053 Cyclamic acid 
PC054 Deoxycholic acid 
PC055 ®-(-)-Deprenyl, Hydrochloride, Selegiline hydrochloride 
PC056 Dequalinium chloride 
PC057 Desalkylflurazepam 
PC058 Dexbrompheniramine maleate 
PC059 Dexchlorpheniramine maleate 
PC060 Diazepam 
PC061 Dibucaine, hydrochloride 
PC062 Dichloroisoproterenol hydrochloride 
PC063 Dicumarol 
PC064 Diethylpropion, hydrochloride 
PC065 Digoxin 
PC066 1,8-Dihydroxyanthrone, Dithranol.  
PC067 Diphenhydramine hydrochloride 
PC068 Diphenylhydantoin, Phenytoin 
PC069 Dipyrone, Metamizol sodium 
PC070 Doxepin hydrochloride 
PC071 Dulcin, p-Phenetylurea 
PC072 Emetine dihydrochloride 
PC073 Ethamivan 
PC074 Ethopropazine hydrochloride 
PC075 Ethyl 4-Hydroxybenzoate 
PC076 Ethylnorepinephrine, 1,2-Benzenediol, 4-(2-amino-1-hydroxybutyl)-(9 Cl) 
PC077 17 Alpha-ethynylestradiol 
PC078 Etilefrin 
PC079 Exaprolol, 2-Propanol, 1-(2-cyclohexylphenoxy)-3-[(1-methylethyl)amino]-(9 Cl) 
PC080 Fenoprofen, calcium salt 
PC081 Fenoterol hydrobromide 
PC082 Cis(Z)-Flupentixol dihydrochloride 
PC083 2-Amino-5-Chloro-2'-Fluorobenzophenone 
PC084 Fluphenatzinemaleate 
PC085 Folic acid 
PC086 Guaifenesin 
PC087 Hexobarbital 
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PC088 Hexoprenaline 
PC089 Homatropine hydrobromide 
PC090 Homotaurine 
PC091 Hydrochlorothiazide 
PC092 Hydrocortisone acetate 
PC093 Hydroxychloroquine sulfate 
PC094 p-Hydroxyephedrine 
PC095 1-(4'-Hydroxy-3'-methylphenyl)-2-(tert-butylamino) ethane, hydrochloride 
PC096 N-Hydroxyethylpromethazine chloride 
PC097 Hydroxyzine, hydrochloride 
PC098 Ibufenac 
PC099 Ibuprofen 
PC100 Inositol 
PC101 Isoetharine 
PC102 (+/-)-Isoproterenol, hemisulfate salt 
PC103 Isoproterenol, hydrochloride, Isoprenaline hydrochloride 
PC104 (S)-(+)-Ketoprofen, (S)-2-(3-Benzoylphenyl)-propionic acid 
PC105 Labetalol hydrochloride 
PC106 Lorazepam 
PC107 Medazepam 
PC108 Mefenamic acid 
PC109 Menadione, 2-Methyl-1,4-naphtoquinone,  
PC110 Mephenesin, [3-o(Tolyloxy)1,2-propanediol] 
PC111 Mephentermine sulfate 
PC112 Mepivacaine hydrochloride 
PC113 Mesoridazine besylate 
PC114 Metaraminol, Bitartrate salt 
PC115 Methdilazine 
PC116 Methoxamine hydrochloride 
PC117 Methylatropine bromide 
PC118 L-Methyldopa 
PC119 Methyl p-hydroxybenzoate, Nipagin M 
PC120 Metipranolol 
PC121 Metronidazole 
PC122 Metyprolol tartrate 
PC123 Nadolol 
PC124 Nadoxolol 
PC125 Nalidixic acid 
PC126 Naproxen 
PC127 Narceine 
PC128 Neomycin sulfate 
PC129 Nicotinamide, Niacinamide 
PC130 Nitrazepam 
PC131 Nitrofurantoin 
PC132 Nitrofurazone 
PC133 Nordefrin, hydrochloride 
PC134 Norethindrone, Norethisterone 
PC135 Norfenefrine 
PC136 Nortriptyline hydrochloride 
PC137 Noscapine 
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PC138 Octopamine hydrochloride 
PC139 Opipramol 
PC140 Ouabain 
PC141 Oxazepam 
PC142 
Oxprenolol, hydrochloride, 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-
,hydrochloride, (2R)-(9 Cl) 
PC143 Oxyphenbutazone 
PC144 Cyclobarbital 
PC145 Pantothenic acid, calcium salt monohydrate 
PC146 Papaverine 
PC147 Penbutolol 
PC148 Pentobarbital 
PC149 Perphenazine 
PC150 Phenacetin 
PC151 Phenacetin 
PC152 5-Fluorouracil 
PC153 Phenobarbital 
PC154 Phenylbutazone 
PC155 L-Phenylephrine hydrochloride  
PC156 Phenyl salicylate 
PC157 Pholedrine, sulfate 
PC158 Phthalylsulfacetamide 
PC159 Phthalylsulfathiazole 
PC160 Pindolol 
PC161 Quinidine 
PC162 Practolol 
PC163 Prednisolone 
PC164 Prednisone 
PC165 Primidone 
PC166 Procainamide hydrochloride 
PC167 Procaine hydrochloride 
PC168 Prochlorperazine 
PC169 Promethazine hydrochloride 
PC170 Pronethalol, Alderlin 
PC171 Propantheline bromide 
PC172 2-(3-carboxyphenyl)propionic acid, Benzeneacetic acid, 3-carboxy-a-methyl-(9 Cl) 
PC173 (+/-)-Verapamil hydrochloride 
PC174 Propranolol hydrochloride 
PC175 Propyphenazone 
PC176 Prothipendyl hydrochloride 
PC177 Protokylol hydrochloride 
PC178 Pyridoxine hydrochloride 
PC179 Pyrilamine maleate 
PC180 Quinidine polygalacturonate 
PC181 Resorcinol 
PC182 Riboflavin 
PC183 Saccharin sodium 
PC184 Salbutamol, Albuterol 
PC185 
(+/-) Salbutamol, Sulfate, Albuteron 4-Hydroxy-3-hydromethylalpha[(tert-
butylamino)methyl]benzyl alcohol 
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PC186 Salicylamide 
PC187 Salicylsalicylic acid, Salicoylsalicylic acid 
PC188 Santonin 
PC189 Sodium phenylethylbarbiturate, Phenobarbital sodium 
PC190 Sodium sulfacetamide 
PC191 Sotalol hydrochloride 
PC192 Sulfacetamide 
PC193 Sulfadiazine 
PC194 Sulfadimethoxine 
PC195 Sulfaethidole 
PC196 Sulfaguanidine 
PC197 Sulfamerazine 
PC198 Sulfameter 
PC199 Sulfamethazine, Sulfamidine 
PC200 Sulfamethizole 
PC201 Sulfamethoxazole 
PC202 Sulfamethoxypyridazine 
PC203 Sulfamethylthiadiazole, Lucosil 
PC204 Sulfamoxole 
PC205 Sulfanilamide 
PC206 N-Sulfanilyl-3.4-xylamide, Irgafen 
PC207 Sulfaperine 
PC208 Sulfapyridine 
PC209 Sulfathiazole 
PC210 Sulfisoxazole 
PC211 Sulfonmethane 
PC212 Talinolol, N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxyproxy]phenyl]- (9 Cl) 
PC213 Temazepam 
PC214 Terbutaline, Hemisulfate salt 
PC215 Tetracaine hydrochloride 
PC216 Theobromine 
PC217 Theophylline 
PC218 7-(2,3-Dihydroxypropyl)Theophylline, Dyphylline, Diprophyllin 
PC219 7- (Beta-hydroxypropyl)-Theophylline, Proxyphylline 
PC220 Thiamine mononitrate 
PC221 Thiethylperazine 
PC222 1,3-Diethyl-2-Thiobarbituric acid, Thiobarbital 
PC223 Thioridazine  
PC224 6-Propyl-2-thiouracil 
PC225 Timolol maleate 
PC226 Tinidazole 
PC227 Tinopal 
PC228 (+)-alpha-Tocopherol acid succinate 
PC229 Tolazoline hydrochloride 
PC230 Tolbutamide 
PC231 Tolfenamic acid 
PC232 Tranylcypromine sulfate 
PC233 Triamterene 
PC234 Triazolam 
PC235 Trimeprazine, tartrate 
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PC236 Urosulfanum, Sulfaninyl urea hydrate 
PC237 Xylometazoline 
PC238 Chlorphentermine 
PC239 Dexamethasone 
PC240 Imipramine hydrochloride 
 
Appendix 2. List of screened natural compounds. 
 
Natural compounds (NC) 
 
 Code Name 
NC001 Acacetin 
NC002 Alpha-naphthoflavone 
NC003 Apigenin 
NC004 L-ascorbic acid 
NC005 Benzoic acid 
NC006 3-Benzoylbenzo(F)coumarin 
NC007 3-(2-Benzoxazolyl)umbelliferone 
NC008 Bergapten, 5-Methoxypsoralen  
NC009 Butylatedhydroxyanisole 
NC010 Caffeic acid 
NC011 (+)-Catechin 
NC012 Catechol 
NC013 Chrysin 
NC014 o-Coumaric acid 
NC015 Coumarin 102 
NC016 Coumarin 30 
NC017 Coumarin 7 
NC018 Coumarin 
NC020 Daidzein 
NC021 Daphnetin 
NC022 7-Diethylamino-3-thenoylcoumarin 
NC023 2,3-Dihydroxybenzoic acid 
NC024 2,5-Dihydroxybenzoic acid 
NC025 2,6-Dihydroxybenzoic acid 
NC026 3,4-Dihydroxybenzoic acid 
NC027 3,5-Dihydroxybenzoic acid 
NC029 2,5-Dimethyl-phenol 
NC030 2,4-Dinitrophenylhydrazine 
NC031 1,1-Diphenyl-2-picrylhydrazine 
NC032 5-Dimethylaminonaphthalene-1-sulfonylchloride 
NC033 Ellagic acid 
NC034 (-)-Epicatechin 
NC035 (-)-Epicatechin gallate 
NC036 (-)-Epigallocatechin  
NC037 (-)-Epigallocatechin gallate 
NC038 Ethoxyquin 
NC039 Ferulic acid 
NC040 Flavon 
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NC041 Gallic acid 
NC042 Genistein 
NC043 Gitoxigenin 
NC044 Gossypin 
NC045 Hamamelitannin 
NC046 Hesperidin 
NC047 2-Hydroxyacetophenone 
NC048 3-hydroxyacetophenone 
NC049 4-Hydroxyacetophenone 
NC050 2-Hydroxyphenylacetic acid 
NC051 3-hydroxyphenylacetic acid 
NC052 4-Hydroxyphenylacetic acid 
NC053 Hydroquinone 
NC054 Isopropyl gallate 
NC055 2,4-dihydroxylbenzoic acid 
NC056 Isorhamnetin 
NC057 Kaempferol 
NC058 Khellin 
NC059 Lauryl gallate 
NC060 Leucocyanidin 
NC061 Luteolin 
NC062 Luteolin-7-glucoside 
NC063 Malvin chloride 
NC064 Methyl gallate 
NC065 Methyl-umbelliferone 
NC066 2'-Methoxy-alpha-naphthoflavone 
NC067 Morin dihydrat 
NC068 Myricetin 
NC070 4-Methyl pyrocatechol 
NC071 Nordihydroguaiaretic acid 
NC072 Octyl gallate 
NC073 Phthalsäure 
NC076 n-Propyl gallate 
NC078 Pyrogallol 
NC079 Quercetagetin 
NC080 Quercetin krist. 
NC082 Quercitrin dihydrat 
NC083 Quercitrin dihydrat 
NC084 (-)-Quinic acid 
NC085 Resorcin 
NC086 Resveratrol 
NC087 Rhamnetin 
NC088 Rosmarinic acid 
NC089 Rotenone 
NC090 Rutin 
NC091 D(-)-Salicin 
NC092 Salicylic acid 
NC093 Silybin 
NC094 Silybin (silymarin) 
NC095 Sinapic acid 
 72!
NC096 Sinigrin monohydrat 
NC097 Syringic acid 
NC098 Tannic acid 
NC099 Camptothecin 
NC100 (+)-Taxifolin 
NC101 Thymol 
NC102 3,4,5-Trimethoxybenzoic acid 
NC103 Trolox 
NC104 Umbelliferon 
NC105 Vanillic acid 
NC106 Vanillin 
NC107 Butylatedihydroxytoluene 
NC108 4-Methylumbelliferone 
NC109 Isoscopoletin 
NC110 Fraxetin 
NC111 Fraxidin 
NC112 Daphnetine 
NC113 Daphnetine-7-methylether 
NC114 Scopoletin 
NC115 Umbelliferone 
NC116 6-Methylcoumarin 
NC117 4-hydroxycoumarin 
NC118 3-(a-Acetonylbenzyl)-4-hydroxycoumarin 
NC119 6-Methoxy-4-methylcoumarin 
NC120 7-Methoxy-4-methylcoumarin 
NC121 Coumarin 
NC122 5,7-dihydroxy-4-methylcoumarin 
NC123 6,7-dihydroxy-4-methylcoumarin 
NC124 Herniarin 
NC125 6,8-Dibromocoumarin carboxylic acid 
NC126 Esculetin 
NC127 Esculin sesquihydrate' 
NC128 Citrophen 
NC129 Xanthotoxin 
NC130 Coumarin 106 
NC131 Coumarin 153 
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Appendix 3. Hits from the primary screening (false positive hits (2) not included). 
 
Compound Class Mechanism of action 
Primary 
screen           
(fold of con-
trol; average ± 
st dev) 
Acetylsulfisoxazole Antibacterial Sulfonamide 2.6 ± 1.2 
Allobarbital Barbiturate GABAAR modulation 3.1 ± 1.2 
Atropine methyl nitrate Anticholinergic Muscarinic antagonist 2.8 ± 0.8 
Busulfan Alkyl sulfonate Antineoplastic 2.6 ± 0.6 
Butethal Barbiturate GABAAR modulation 3.4 ± 0.9 
Butidrine Adrenergic b antagonist 2.7 ± 0.6 
Cetrimonium bromide Topical antiseptic Cationic surfactant 5.2 ± 1.2 
Chlorothiazide Diurete Na+-Cl- Symporter inhibition 2.6 ± 0.7 
Cinchophen Analgesic - 2.7 ± 0.8 
Clopenthixol dihydrochloride Antipsychotic D1R/D2R antagonist 3.7 ± 0.5 
Dequalinium chloride Antiseptic Bisquanternary quinolinium 2.6 ± 0.9 
Desalkylflurazepam Benzodiazepine GABAAR modulation 3.5 ± 1.1 
Dexbrompheniramine 
maleate Antiallergic Histamine H1R antagonist 3.4 ± 0.6 
Dexchlorpheniramine 
maleate Antiallergic Histamine H1R antagonist 2.5 ± 0.7 
Diazepam Benzodiazepine GABAAR modulation 2.9 ± 0.9 
Dicumarol Anticoagulant Competitive inhibitor of vitamin K 0.7 ± 0.1 
Folic acid Vitamin One-carbon metabolism 0.7 ± 0.2 
Mepivacaine HCl Local anesthetic Na+-channel inhibition 0.7 ± 0.1 
Octopamine HCl Biogenic amine Adrenergic 2.1 ± 0.6 
Pentobarbital Barbiturate GABAAR modulation 2.1 ± 0.3 
Phthalylsulfathiazole Antibacterial Sulfonamide 2.2 ± 0.5 
Selegiline HCl Antiparkinsonian MAO inhibition 3.5 ± 1.6 
Sulfameter Antibacterial Sulfonamide 2.1 ± 0.2 
Tolbutamide Hypoglycemic K+-channel blocker 2.2 ± 0.6 
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Appendix 4. Compounds used in the secondary screening. 
 
Compound Class Mechanism of action 
Primary screen         
(fold of control; 
average ± st 
dev) 
Average ef-
fect (n=4 
repeats; fold 
of control) 
Desalkylflurazepam Benzodiazepine GABAAR modulation 3.5 ± 1.1 2.1 ± 0.14 
Clopenthixol dihy-
drochloride Antipsychotic D1R/D2R antagonist 3.7 ± 0.5 2.0 ± 0.21 
Allobarbital Barbiturate GABAAR modulation 3.1 ± 1.2  1.9 ± 0.38 
Butethal Barbiturate GABAAR modulation 3.4 ± 0.9 1.9 ± 0.12 
Acetylsulfisoxazole Antibacterial Sulfonamide 2.6 ± 1.2 1.9 ± 0.70 
Selegiline HCl Antiparkinsonian MAO inhibition 3.5 ± 1.6 1.8 ± 0.20 
Diazepam Benzodiazepine GABAAR modulation 2.9 ± 0.9 1.7 ± 0.42 
Sulfameter Antibacterial Sulfonamide 2.1 ± 0.2 1.6 ± 0.71 
Dexbrompheniramine 
maleate Antiallergic Histamine H1R antagonist 3.4 ± 0.6 1.5 ± 0.71 
Octopamine HCl Biogenic amine Adrenergic 2.1 ± 0.6 1.4 ± 0.57 
Pentobarbital Barbiturate GABAAR modulation 2.1 ± 0.3 1.4 ± 0.28 
Tolbutamide Hypoglycemic K-channel blocker 2.2 ± 0.6 0.9 ± 0.01 
Phthalylsulfathiazole Antibacterial Sulfonamide 2.2 ± 0.5 0.8 ± 0.02 
Folic acid Vitamin  One-carbon metabolism 0.7 ± 0.2 0.7 ± 0.04 
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